Primer and probe for detecting mycobacteria

The PCR method using specific primer combinations and probes solves the problems of long detection time and insufficient detail in existing mycobacterial detection technologies, achieving rapid, detailed and specific mycobacterial detection, which is suitable for safety testing of biological samples and pharmaceutical products.

CN118946667APending Publication Date: 2024-11-12SANOFI VACCINE DEVELOPMENT CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380030359.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-31
Filing Date
2023-03-31
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing technologies cannot quickly, effectively, and comprehensively detect mycobacteria in biological samples and pharmaceutical products, especially slow-growing or intracellular parasitic strains, posing safety risks and excessively long detection times.

Method used

The rrs gene of mycobacteria is amplified by PCR using a specific primer combination and detected by corresponding probes. This method includes at least three primer pairs and related probes and is suitable for the detection of mycobacteria in eukaryotic cells.

Benefits of technology

It enables comprehensive, rapid, and specific detection of mycobacteria, capable of identifying all known mycobacterial species, regardless of their growth rate or classification, and is suitable for safety release testing of biopharmaceutical products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005059516650000301
    Figure BDA0005059516650000301
  • Figure BDA0005059516650000311
    Figure BDA0005059516650000311
  • Figure BDA0005059516650000312
    Figure BDA0005059516650000312
Patent Text Reader

Abstract

The present invention relates to a primer set for amplifying the sequence of any mycobacterial rrs gene present in a sample by polymerase chain reaction (PCR) wherein the set comprises at least three primer pairs and allows amplification of the sequence of the rrs gene from any mycobacterial species. The invention also relates to a probe associated with said primer pair, said probe allowing the specific detection of the mycobacterial rrs sequence amplified by said primer pair. The invention also relates to different methods and uses of these primers and probes to detect the presence of Mycobacterium in any product, in particular a pharmaceutical product such as a vaccine, in detail and specifically.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to the field of detection of mycobacteria, in particular to biological samples and pharmaceutical products. The present invention also relates to safety release tests for the detection of mycobacteria, which are required for all products expressed in or based on eukaryotic cells, in particular vaccines. The present invention also relates to oligonucleotides, in particular primers and probes, which can be used to specifically and exhaustively detect mycobacteria in a sample. Background Art

[0002] Mycobacteria are part of the family Mycobacteriaceae. The phylogeny and nomenclature of mycobacteria are rapidly evolving. Prior to February 2018, all species of mycobacteria were classified into a single genus, Mycobacterium. Since then and since the publication of the 2018 paper by Gupta R. et al., more than 188 species of mycobacteria have been cited, which are classified into five different genera, namely Mycobacterium, Mycobacteroides, Mycolicibacterium, Mycolicibacter, and Mycolicibacillus.

[0003] In addition, the nomenclature has been slightly modified recently (see Riojas MA et al., 2018). It is now recognized that there are 200 recognized mycobacterial species, 6 of which contain subspecies or variants, so there are 217 recognized mycobacterial species, subspecies or variants. Subsequent changes have modified the classification of mycobacteria, reconstructing a single genus Mycobacterium, but have not modified the strains considered mycobacteria nor their numbering (Meehan CJ et al., 2021).

[0004] Among these different species, some of them are pathogenic to humans, such as Mycobacterium tuberculosis (the causative agent of tuberculosis) and Mycobacterium leprae (the causative agent of leprosy).

[0005] Other mycobacteria, called nontuberculous mycobacteria (NTM), can be opportunistic pathogens in humans, associated with pulmonary and extrapulmonary infections ( M. avium and M. marinum , respectively). However, other species are commensal bacteria.

[0006] The growth kinetics of mycobacteria vary widely and are much slower than those of most other bacteria; in fact, fast-growing mycobacteria have a reproductive cycle of approximately 48 to 72 hours, while for slow-growing species, the reproductive cycle can be between 10 days and 2 months. For comparison, the growth rate of Escherichia coli (E. coli) is 20 minutes.

[0007] Mycobacteria are widely distributed in various environments (such as water and soil) and may have several hosts (humans, cattle, protozoa), which makes their detection extremely challenging (Haig et al., 2018). During the production process, mycobacteria may potentially contaminate biopharmaceutical products (such as vaccines) through raw materials (such as cells and serum) of animal or human origin used in the process. The contamination may also be introduced by operators or by the environment (such as water).

[0008] Therefore, mycobacteria are screened in vaccine products (especially non-inactivated viral vaccine products), as well as in cell banks and virus seed banks used in vaccine production.

[0009] Mycobacterium testing is a safety release test that may be required for all biological or drug products expressed in or based on eukaryotic cells. The European Pharmacopoeia has this requirement for viral vaccines at the virus seed batch and virus harvest stage; the Japanese and Chinese Pharmacopoeias have equivalent requirements; and mycobacterium testing is also performed in the United States to ensure the safety of drug products.

[0010] The current method described in the European Pharmacopoeia for safety release testing is based on microbial culture (see European Pharmacopoeia Chapter 2.6.2 and WHO Technical Report Series-TRS 978). It requires the sample to be inoculated in triplicate onto two suitable solid media ( -Jensen's medium and Middlebrook 7H10 medium were considered as suitable solid media) and in a suitable liquid medium. All media were incubated at 36.5°C ± 1.5°C for 56 days.

[0011] The main problems and limitations of the above-mentioned pharmacopeia culture-based assays are, among others: the availability and potential shortage of specific culture media, the very long time to obtain results (56 days), and the lack of detection of some mycobacteria, such as M. intracellulare. An important species of human origin, M. leprae, which is an obligate intracellular parasite, is not detected by the above-mentioned test. Therefore, there are also safety risks associated with the lack of detection of this species according to the pharmacopeia method. The culture-based assays are also unable to detect fastidious species with specific growth requirements, such as M. genavense, which requires longer incubation times (i.e., 8-12 weeks), or M. haemophilum, which requires iron culture medium supplementation).

[0012] Some alternative methods have been disclosed in the art, which are based on PCR (polymerase chain reaction) or qPCR (quantitative PCR) and target different regions of the mycobacterial genome. These methods have the potential to overcome at least some of the limitations of the culture-based techniques, as they target bacterial DNA and therefore should not be limited by the necessity of culturing microorganisms.

[0013] However, some of these alternative qPCR-based techniques developed for the detection of mycobacteria are tied to culture days and thus still require at least a month to complete. Therefore, these approaches do not address the time limitations of the pharmacopeia culture-based assays nor the problem of detecting intracellular mycobacteria.

[0014] Other methods have been developed using qPCR targeting ITS sequences and 16S sequences, but based on previous taxonomies of Mycobacterium (2018). These methods generally show a lack of sensitivity and / or susceptibility, especially when applied to new taxonomies (2018).

[0015] Another technique has been developed based on filtration of high volumes (water samples), immunocapture and qPCR targeting the hsp65 gene. However, this technique does not ensure a sufficiently high sensitivity, since not all mycobacteria can be detected according to this method.

[0016] Indeed, given the lack of data on corresponding sequences for all mycobacterial species, there are strong indications that the sequences targeted in the methods disclosed in the prior art do not allow an exhaustive detection of mycobacteria, which represents an important safety risk.

[0017] Finally, most of the sequences targeted by these alternative approaches are not unique to mycobacteria, resulting in amplification of non-mycobacterial sequences, leading to false-positive and unreliable results.

[0018] Furthermore, it is important to emphasize that the PCR-based detection methods disclosed in the art are mostly intended for diagnostic purposes, detecting only mycobacteria that are pathogenic to humans, such that exhaustiveness of the genus Mycobacterium is not even a goal, and the same is true for specificity. Similarly, most methods are intended for testing samples obtained from patients that may present important mycobacterial concentrations; such that the sensitivity is not tested, and / or the sensitivity is too low to be compatible with the detection of contamination in biological drug products (which requires detection at concentrations typically below 100 viable mycobacteria / mL).

[0019] Therefore, none of the prior art provides the required safety, efficiency and robustness to meet the requirements for safety release testing. Therefore, there remains a pressing need for alternatives to pharmacopoeial methods that have improved exhaustiveness and are faster. Therefore, there remains a pressing need for alternatives to pharmacopoeial methods that provide the same specificity, but have improved exhaustiveness, and are effective, robust and faster. Therefore, there remains a pressing need for alternatives to pharmacopoeial methods that provide the same specificity, but have improved exhaustiveness, and are effective, robust and faster, and can be as sensitive as pharmacopoeial methods.

[0020] Using genomic analysis and bioinformatics applied to the new taxonomy, the inventors unexpectedly found a primer combination that is suitable for PCR and detects all known strains and species of mycobacteria. Thus, a method based on this combination allows the detection of mycobacterial species in a sample in an exhaustive manner, i.e., the detection of any species of mycobacteria that may be present, regardless of the classification of the mycobacterium, regardless of whether it is a human pathogen or not, regardless of whether it is a fast-growing or slow-growing mycobacterium, regardless of whether the mycobacteria are in high concentrations as in human body fluid samples, or in very low concentrations as contaminants.

[0021] Furthermore, the inventors have discovered a combination of primers and probes that can specifically detect all known strains and species of mycobacteria. Thus, a method based on this combination allows the specific detection of mycobacterial species in a sample in an exhaustive and specific manner, i.e., the detection of any species, subspecies or variant of mycobacteria, but not other bacteria, especially not phylogenetically close species. Summary of the invention

[0022] The present invention relates to a primer set for amplifying the sequence of any mycobacterial rrs gene present in a sample by polymerase chain reaction (PCR), wherein the set comprises at least three of the following primer pairs:

[0023] Pair 1:

[0024] Forward primer F1, which has the sequence: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) or a modification thereof,

[0025] Reverse primer R1 having the sequence: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2) or a modification thereof;

[0026] Pair 2:

[0027] Forward primer F3, which has the sequence: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) or a modification thereof,

[0028] Reverse primer R3, which has the sequence: 5'-CATGCACCACCTGCACACA-3' (SEQ ID

[0029] NO:5) or its modification;

[0030] Pair 3:

[0031] Forward primer F4, which has the sequence: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7) or a modification thereof,

[0032] Reverse primer R4, which has the sequence: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID

[0033] NO:8) or its modification;

[0034] wherein the modification is an addition and / or deletion of 1 to 4 nucleotides at the 3' and / or 5' termini, and / or a substitution of 1 or 2 nucleotides, and

[0035] The three primer pairs described allow amplification of sequences of the rrs gene from any mycobacterial species.

[0036] According to a specific embodiment, the first primer pair is selected from:

[0037] 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0038] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0039] 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0040] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0041] 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0042] Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12);

[0043] 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2);

[0044] 5) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-3: 5'-CACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 27);

[0045] 6) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12);

[0046] 7) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13);

[0047] as well as

[0048] 8) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0049] Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13).

[0050] According to a specific embodiment, the second primer pair is selected from:

[0051] 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0052] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0053] 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0054] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0055] 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0056] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0057] 4) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0058] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0059] 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0060] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0061] 6) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0062] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0063] 7) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0064] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17).

[0065] as well as

[0066] 8) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0067] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17).

[0068] According to a specific embodiment, the third primer pair is selected from:

[0069] 1) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0070] 2) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0071] 3) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0072] Reverse primer R4-1: 5′-GGCATCGCAGCCCTTTG-3′ (SEQ ID NO: 8);

[0073] 4) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0074] 5) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-5: 5'-GCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 28);

[0075] 6) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0076] 7) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0077] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0078] as well as

[0079] 8) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0080] Reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

[0081] The present invention also relates to a kit for amplifying the sequence of the Mycobacterium rrs gene in a sample by PCR, said kit comprising a primer set as defined above.

[0082] According to one embodiment, the kit is used to detect the Mycobacterium rrs gene sequence amplified by PCR in a sample, and further comprises the following relevant probes for detecting one or more amplification products:

[0083] - Probe S1, which has the sequence 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3) or a modification thereof, for detecting the sequence amplified by the primers F1 and R1;

[0084] - Probe S3, which has the sequence: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6) or a modification thereof, for detecting the sequence amplified by the primers F3 and R3;

[0085] - a probe S4 having the sequence: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) or a modification thereof, for detecting the sequence amplified by the primers F4 and R4,

[0086] The modification is the addition and / or deletion of 1 to 2 nucleotides at the 3' and / or 5' terminus.

[0087] According to one embodiment, the probe is selected from:

[0088] a) For the probe S1, selected from:

[0089] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and

[0090] Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23);

[0091] Wherein when the probe S1 is S1-1, the first primer pair is selected from:

[0092] 1) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-1 (SEQ ID NO: 2);

[0093] 2) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-6 (SEQ ID NO: 13);

[0094] 3) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-5 (SEQ ID NO: 12);

[0095] 4) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-1 (SEQ ID NO: 2);

[0096] as well as

[0097] 5) forward primer F1-3 (SEQ ID NO: 11) and reverse primer R1-6 (SEQ ID NO: 13);

[0098] When the probe S1 is S1-2, the first primer pair is selected from:

[0099] 1) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-1 (SEQ ID NO: 2);

[0100] 2) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-6 (SEQ ID NO: 13);

[0101] 3) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-5 (SEQ ID NO: 12);

[0102] 4) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-1 (SEQ ID NO: 2);

[0103] 5) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-5 (SEQ ID NO: 12);

[0104] as well as

[0105] 6) forward primer F1-3 (SEQ ID NO: 11) and reverse primer R1-6 (SEQ ID NO: 13);

[0106] b) For the probe S3, selected from:

[0107] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and

[0108] Probe S3-2: 5′-CGGTTCCCTTGTGGC-3′ (SEQ ID NO: 25);

[0109] Wherein when the probe S3 is S3-1, the second primer pair is selected from:

[0110] 1) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-1 (SEQ ID NO: 5);

[0111] 2) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-1 (SEQ ID NO: 5);

[0112] 3) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-2 (SEQ ID NO: 15);

[0113] 4) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-2 (SEQ ID NO: 15);

[0114] as well as

[0115] 5) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-3 (SEQ ID NO: 16);

[0116] When the probe S3 is S3-2, the second primer pair is selected from:

[0117] 1) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-1 (SEQ ID NO: 5);

[0118] 2) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-1 (SEQ ID NO: 5);

[0119] 3) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-2 (SEQ ID NO: 15);

[0120] 4) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-3 (SEQ ID NO: 16);

[0121] 5) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-4 (SEQ ID NO: 17);

[0122] as well as

[0123] 6) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-3 (SEQ ID NO: 16);

[0124] c) For the probe S4, selected from:

[0125] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and

[0126] Probe S4-1: 5′-ACATGCTACAATGGCCGGT-3′ (SEQ ID NO: 26);

[0127] Wherein when the probe S4 is S4-1, the third primer pair is selected from:

[0128] 1) forward primer F4-1 (SEQ ID NO: 7) and reverse primer R4-1 (SEQ ID NO: 8);

[0129] 2) forward primer F4-3 (SEQ ID NO: 18) and reverse primer R4-1 (SEQ ID NO: 8);

[0130] 3) forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-1 (SEQ ID NO: 8);

[0131] 4) forward primer F4-1 (SEQ ID NO: 7) and reverse primer R4-3 (SEQ ID NO: 20);

[0132] 5) forward primer F4-3 (SEQ ID NO: 18) and reverse primer R4-3 (SEQ ID NO: 20);

[0133] 6) forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-3 (SEQ ID NO: 20);

[0134] as well as

[0135] 7) Forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-6 (SEQ ID NO: 21).

[0136] In one embodiment, the kit is for amplification by quantitative polymerase chain reaction (qPCR) or by digital polymerase chain reaction (dPCR).

[0137] The present invention also relates to a method for amplifying and detecting the sequence of the rrs gene of any mycobacterium present in a sample, the method comprising the following steps performed simultaneously or sequentially:

[0138] a) performing in vitro PCR on nucleic acids extracted from said sample using a set of at least three primer pairs disclosed above;

[0139] b) Detecting the presence or absence of the amplified product.

[0140] The amplification step a) can be performed, for example, by quantitative PCR or digital PCR.

[0141] According to one embodiment, the detection step b) is performed using the following relevant probes:

[0142] i. Probe S1 selected from:

[0143] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and

[0144] Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23);

[0145] Wherein when the probe S1 is S1-1, the first primer pair is selected from:

[0146] 1) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-1 (SEQ ID NO: 2);

[0147] 2) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-6 (SEQ ID NO: 13);

[0148] 3) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-5 (SEQ ID NO: 12);

[0149] 4) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-1 (SEQ ID NO: 2);

[0150] as well as

[0151] 5) forward primer F1-3 (SEQ ID NO: 11) and reverse primer R1-6 (SEQ ID NO: 13);

[0152] When the probe S1 is S1-2, the first primer pair is selected from:

[0153] 1) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-1 (SEQ ID NO: 2);

[0154] 2) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-6 (SEQ ID NO: 13);

[0155] 3) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-5 (SEQ ID NO: 12);

[0156] 4) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-1 (SEQ ID NO: 2);

[0157] 5) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-5 (SEQ ID NO: 12);

[0158] as well as

[0159] 6) forward primer F1-3 (SEQ ID NO: 11) and reverse primer R1-6 (SEQ ID NO: 13);

[0160] ii. Probe S3 selected from:

[0161] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and

[0162] Probe S3-2: 5′-CGGTTCCCTTGTGGC-3′ (SEQ ID NO: 25);

[0163] Wherein when the probe S3 is S3-1, the second primer pair is selected from:

[0164] 1) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-1 (SEQ ID NO: 5);

[0165] 2) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-1 (SEQ ID NO: 5);

[0166] 3) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-2 (SEQ ID NO: 15);

[0167] 4) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-2 (SEQ ID NO: 15);

[0168] as well as

[0169] 5) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-3 (SEQ ID NO: 16);

[0170] When the probe S3 is S3-2, the second primer pair is selected from:

[0171] 1) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-1 (SEQ ID NO: 5);

[0172] 2) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-1 (SEQ ID NO: 5);

[0173] 3) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-2 (SEQ ID NO: 15);

[0174] 4) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-3 (SEQ ID NO: 16);

[0175] 5) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-4 (SEQ ID NO: 17);

[0176] as well as

[0177] 6) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-3 (SEQ ID NO: 16);

[0178] iii. Probe S4 selected from:

[0179] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and

[0180] Probe S4-1: 5′-ACATGCTACAATGGCCGGT-3′ (SEQ ID NO: 26);

[0181] Wherein when the probe S4 is S4-1, the third primer pair is selected from:

[0182] 1) forward primer F4-1 (SEQ ID NO: 7) and reverse primer R4-1 (SEQ ID NO: 8);

[0183] 2) forward primer F4-3 (SEQ ID NO: 18) and reverse primer R4-1 (SEQ ID NO: 8);

[0184] 3) forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-1 (SEQ ID NO: 8);

[0185] 4) forward primer F4-1 (SEQ ID NO: 7) and reverse primer R4-3 (SEQ ID NO: 20);

[0186] 5) forward primer F4-3 (SEQ ID NO: 18) and reverse primer R4-3 (SEQ ID NO: 20);

[0187] 6) forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-3 (SEQ ID NO: 20);

[0188] as well as

[0189] 7) Forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-6 (SEQ ID NO: 21).

[0190] The method may comprise an initial step of extracting said nucleic acid from said sample before carrying out step a).

[0191] The present invention also relates to a method for detecting the presence of mycobacterial contamination in a pharmaceutical product without any culturing step, said method comprising the following steps performed simultaneously:

[0192] a) amplifying in vitro nucleic acids extracted from a sample of the product by quantitative PCR (qPCR) or dPCR using at least three primer pairs as described above, wherein the primers hybridize to the rrs gene,

[0193] b) Detecting the presence or absence of the amplified product by the following probes:

[0194] i. Probe S1 selected from:

[0195] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and

[0196] Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23);

[0197] Wherein when the probe S1 is S1-1, the first primer pair is selected from:

[0198] 1) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-1 (SEQ ID NO: 2);

[0199] 2) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-6 (SEQ ID NO: 13);

[0200] 3) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-5 (SEQ ID NO: 12);

[0201] 4) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-1 (SEQ ID NO: 2);

[0202] as well as

[0203] 5) forward primer F1-3 (SEQ ID NO: 11) and reverse primer R1-6 (SEQ ID NO: 13);

[0204] When the probe S1 is S1-2, the first primer pair is selected from:

[0205] 1) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-1 (SEQ ID NO: 2);

[0206] 2) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-6 (SEQ ID NO: 13);

[0207] 3) forward primer F1-1 (SEQ ID NO: 1) and reverse primer R1-5 (SEQ ID NO: 12);

[0208] 4) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-1 (SEQ ID NO: 2);

[0209] 5) forward primer F1-2 (SEQ ID NO: 10) and reverse primer R1-5 (SEQ ID NO: 12);

[0210] as well as

[0211] 6) forward primer F1-3 (SEQ ID NO: 11) and reverse primer R1-6 (SEQ ID NO: 13);

[0212] ii. Probe S3 selected from:

[0213] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and

[0214] Probe S3-2: 5′-CGGTTCCCTTGTGGC-3′ (SEQ ID NO: 25);

[0215] Wherein when the probe S3 is S3-1, the second primer pair is selected from:

[0216] 1) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-1 (SEQ ID NO: 5);

[0217] 2) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-1 (SEQ ID NO: 5);

[0218] 3) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-2 (SEQ ID NO: 15);

[0219] 4) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-2 (SEQ ID NO: 15);

[0220] as well as

[0221] 5) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-3 (SEQ ID NO: 16);

[0222] When the probe S3 is S3-2, the second primer pair is selected from:

[0223] 1) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-1 (SEQ ID NO: 5);

[0224] 2) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-1 (SEQ ID NO: 5);

[0225] 3) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-2 (SEQ ID NO: 15);

[0226] 4) forward primer F3-1 (SEQ ID NO: 4) and reverse primer R3-3 (SEQ ID NO: 16);

[0227] 5) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-4 (SEQ ID NO: 17);

[0228] as well as

[0229] 6) forward primer F3-3 (SEQ ID NO: 14) and reverse primer R3-3 (SEQ ID NO: 16);

[0230] iii. Probe S4 selected from:

[0231] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and

[0232] Probe S4-1: 5′-ACATGCTACAATGGCCGGT-3′ (SEQ ID NO: 26);

[0233] Wherein when the probe S4 is S4-1, the third primer pair is selected from:

[0234] 1) forward primer F4-1 (SEQ ID NO: 7) and reverse primer R4-1 (SEQ ID NO: 8);

[0235] 2) forward primer F4-3 (SEQ ID NO: 18) and reverse primer R4-1 (SEQ ID NO: 8);

[0236] 3) forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-1 (SEQ ID NO: 8);

[0237] 4) forward primer F4-1 (SEQ ID NO: 7) and reverse primer R4-3 (SEQ ID NO: 20);

[0238] 5) forward primer F4-3 (SEQ ID NO: 18) and reverse primer R4-3 (SEQ ID NO: 20);

[0239] 6) forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-3 (SEQ ID NO: 20);

[0240] as well as

[0241] 7) Forward primer F4-5 (SEQ ID NO: 19) and reverse primer R4-6 (SEQ ID NO: 21).

[0242] The amplification step a) can be performed simultaneously with the three primer pairs and the relevant probes, for example in a single reaction mixture.

[0243] According to yet another embodiment, the present application also relates to a method for producing a biopharmaceutical product, the method comprising a step of detecting mycobacterial contamination by performing the method of the present invention disclosed above for detecting the sequence of the rrs gene of any mycobacterium. The step of testing mycobacterial contamination can be performed at any one or more stages during the manufacture of the biopharmaceutical product, for example, on raw materials (such as cell matrix and / or virus seed and / or culture medium and / or cell culture), and / or on biopharmaceutical product harvest and / or on formulated biopharmaceutical products and / or on filled biopharmaceutical products. When the raw material or biopharmaceutical product (i.e., a sample from the raw material or biopharmaceutical product) is detected to be contaminated with mycobacteria according to the method of the present invention disclosed above, the raw material or the biopharmaceutical product is discarded from the production method. By testing according to the method of the present invention disclosed above, a product (such as a raw material or biopharmaceutical product) determined to be free of mycobacterial contamination (i.e., its sample is determined to be free of mycobacterial contamination) is maintained in the production method. This method for producing a biopharmaceutical product may further comprise the step of releasing the biopharmaceutical product having passed said test based on the absence of detection of any amplification product by using the three primer pairs and associated probes of the present invention.

[0244] The method for producing a biopharmaceutical product may be a method for producing a biopharmaceutical product free of mycobacterial contamination, comprising the steps of providing a biopharmaceutical product and subjecting the biopharmaceutical product to the method of the present invention as disclosed above for detecting the sequence of the rrs gene of any mycobacterium.

[0245] The biopharmaceutical product may be a biological product or a pharmaceutical product; a suitable product is a vaccine.

[0246] Further uses and methods based on said primers and said probes are also part of the present invention.

[0247] definition:

[0248] Mycobacterium: Mycobacterium according to the present invention is a bacterium of the Mycobacteriaceae family according to the classification of February 2018 (Gupta et al., 2018) completed by newly identified species. Currently, at the date of the present invention, this family includes 217 species, subspecies or variants from the following previously defined genera: Mycobacterium pseudobacterium, Mycobacterium acidobacillus, Mycobacterium acidobacillus, Mycobacterium acidobacillus and Mycobacterium; This represents 217 different sequences. These different species and subspecies or variants are detailed in Table 4, which correspond to mycobacteria whose sequences have been verified by publications; These bacteria are considered as mycobacteria in the present invention, regardless of their classification in the Mycobacteriaceae family.

[0249] Mycobacterium-specific amplification of a target sequence refers to amplification of the target sequence in all relevant species of Mycobacterium (ie, in all 217 species, subspecies or variants).

[0250] Mycobacterium species hereinafter refers to any of these 217 species, subspecies or variants. BRIEF DESCRIPTION OF THE DRAWINGS

[0251] Figure 1A and Figure 1B : Comparison of amplification curves of singleplex and duplex amplification.

[0252] The figures show the fluorescence intensity at the wavelength corresponding to the fluorophore FAM (i.e., the fluorophore of probe S1-0) for amplification / detection performed in singleplex (using primers / probes of F1-1 / R1-1 / S1-0 only or of internal control IC only) or duplex (using primers / probes of both F1-1 / R1-1 / S1-0 and internal control IC) for samples containing different concentrations of DNA extracted from M. tuberculosis var BCG and a fixed concentration of internal control (IC). Figure 1A ), and at a wavelength corresponding to the fluorophore Cy5 (i.e., the fluorophore of the probe used for the internal control (IC)) ( Figure 1B ) that varies with the number of PCR cycles.

[0253] The x-axis represents the cycle number of PCR, and the Y-axis represents the fluorescence level on a logarithmic scale.

[0254] Figure 1A : Top: Amplification in singleplex (diamond ◆) with primers / probe of internal control (singleplex IC), and in duplex (circle ●) with primers / probe of internal control and F1-1 / R1-1 / S1-0. Samples were spiked with DNA of internal control and different concentrations of M. tuberculosis BCG variants.

[0255] Lower panel: Amplification in singleplex (diamonds ◆) with primers / probe F1-1 / R1-1 / S1-0 (singleplex 16S), and in duplex (circles ●) with primers / probe for internal control and F1-1 / R1-1 / S1-0. The samples were spiked with DNA of the internal control and different concentrations of M. tuberculosis BCG variants.

[0256] Figure 1B : Amplification of samples spiked with DNA of internal control and M. tuberculosis BCG variants (stars★) and unspiked samples (squares■) in singleplex (with primers / probe of internal control) and in duplex (with primers / probe of internal control and F1-1 / R1-1 / S1-0).

[0257] Figure 2 : Comparison of amplification curves of duplex and quadruplex amplification.

[0258] This figure shows the fluorescence level at the wavelength corresponding to the fluorophore FAM (i.e., the fluorophore of probes S1-0, S3-0 and S4-0) as a function of the PCR cycle number for amplification / detection performed in duplex or in quadruplex for samples containing DNA of different concentrations of Mycobacterium tuberculosis BCG variants and an internal control.

[0259] The x-axis represents the cycle number of PCR, and the Y-axis represents the fluorescence level on a logarithmic scale.

[0260] Figure 2 A: Comparison of quadruplex amplification curves with duplex amplification curves using only system 1 (F1-R1 / S1 corresponding to F1-1 / R1-1 / S1-0) as well as internal control and relevant primers and probes (IC).

[0261] Figure 2 B: Comparison of quadruplex amplification curves with duplex amplification curves using only system 3 (F3-R3 / S3 corresponding to F3-1 / R3-1 / S3-0) as well as internal control and relevant primers and probe (IC).

[0262] Figure 2 C: Comparison of quadruplex amplification curves with duplex amplification curves using only the 4th system (F4-R4 / S4 corresponding to F4-1 / R4-1 / S4-0) along with the internal control and the relevant primers and probe (IC).

[0263] Figure 3A-Figure 3F :Amplification curves of rrs genes of different mycobacteria (detected by FAM).

[0264] The extracted DNA is shown as "pure" and at different dilutions 10 -1 , 10 -2 and 10 -3 The obtained curve.

[0265] Figure 3A-3C : 6 slow-growing mycobacteria: Mycobacterium tuberculosis BCG variant and Mycobacterium hiberniae ( Figure 3A ), Mycobacterium avium and Mycobacterium terrae (M.terrae) ( Figure 3B ), Mycobacterium xenopi and Mycobacterium kansaii ( Figure 3C ).

[0266] Figure 3D-Figure 3F : 6 fast-growing mycobacteria: M. flavescens and M. smegmatis ( Figure 3D ), Mycobacterium abscessus (M. abscessus) and Mycobacterium fortuitum (M. fortuitum) ( Figure 3E ), Mycobacterium phlei (M. phlei) and Mycobacterium chelonae (M. chelonae) ( Figure 3F ).

[0267] Figure 4 : Amplification curves of the rrs gene in different samples containing 100 live mycobacteria / mL of Mycobacterium tuberculosis BCG variant (positive control) and also 100 colony forming units (CFU) / mL of different actinomycetes (detected with FAM).

[0268] The x-axis represents the cycle number of PCR, and the Y-axis represents the fluorescence level on a logarithmic scale.

[0269] Figure 4 A: Comparison of amplification curves obtained with M. tuberculosis BCG variants and 100 CFU / mL of N. asteroides. N. asteroides was not amplified by mycobacterial qPCR (cycle threshold > 40).

[0270] Figure 4 B: Comparison of amplification curves obtained with M. tuberculosis BCG variants and 100 CFU / mL of D. papillomatosis. D. papillomatosis was not amplified by mycobacterial qPCR (cycle threshold > 40).

[0271] Figure 5 :With or without different concentrations of Mycobacterium tuberculosis BCG variants (10 5 Amplification curves of the rrs gene in different matrices (detected by FAM) with 10 to 10 viable mycobacteria / mL.

[0272] The x-axis represents the cycle number of PCR, and the Y-axis represents the fluorescence level on a logarithmic scale.

[0273] Figure 5 A: Comparison of amplification curves obtained with a matrix corresponding to the CHO cell supernatant used for CMV production spiked with different concentrations of M. tuberculosis BCG variants (10, 100, 10 3 , 10 4 and 10 5 viable mycobacteria / mL, two replicates for each concentration) (star★) or unspiked (circle●).

[0274] Figure 5 B: Comparison of amplification curves obtained with a matrix corresponding to a crude harvest of the drug substance from HAV produced on MRC5 cells spiked with two different concentrations of M. tuberculosis BCG variants (10 and 10 5 live mycobacteria / mL, six replicates per concentration) (star★) or unspiked (diamond◆).

[0275] Figure 5 C: Comparison of amplification curves obtained with a matrix corresponding to the crude harvest from the drug substance of the yellow fever virus vaccine produced on Vero cells spiked with two different concentrations of M. tuberculosis BCG variants (10 and 10 5 viable mycobacteria / mL, six replicates per concentration) (star★) or unspiked (square■).

[0276] Figure 6 : Amplification curves of the rrs gene of different mycobacteria present at 1 or 0.1 mycobacteria / mL matrix (Vero cells) (detected by FAM).

[0277] The x-axis represents the cycle number of PCR, and the Y-axis represents the fluorescence level on a logarithmic scale.

[0278] Figure 6 A: Comparison of amplification curves obtained with a matrix corresponding to Vero cells spiked with M. avium at 1 viable mycobacterium / mL (stars★) or not (circles●).

[0279] Figure 6B: Comparison of amplification curves obtained with a matrix corresponding to Vero cells spiked with M. irishigianum at 1 viable mycobacterium / mL (stars★) or not (circles●).

[0280] Figure 6 C: Comparison of amplification curves obtained with a matrix corresponding to Vero cells spiked with 0.1 viable mycobacteria / mL of M. phlei (stars★) or not (circles●). DETAILED DESCRIPTION

[0281] The inventors unexpectedly discovered a combination of primers that is suitable for PCR and leads to mycobacterium-specific amplification of the target gene (i.e., the rrs gene). Thus, a method based on this primer combination allows the detection of mycobacterial species (i.e., all known strains and species of mycobacteria) in a sample in an exhaustive manner, i.e., the detection of any species, subspecies or variant of mycobacteria that may be present. Furthermore, the minimal primer combination contains only 6 primers, making simultaneous amplification with all primers possible.

[0282] According to a first aspect, the present invention relates to a primer set for amplifying the sequence of the rrs gene of mycobacteria by polymerase chain reaction (PCR), and more specifically to a primer set for amplifying the rrs gene of any potential bacteria classified as mycobacteria. Therefore, the primer set covers the entire Mycobacteriaceae family according to the classification of February 2018 (Gupta et al., 2018), as well as new bacteria classified as mycobacteria; and also covers all mycobacteria of the genus Mycobacterium according to the latest classification (Meehan CJ et al., 2021).

[0283] The primer set of the present invention covers the entire Mycobacteraceae family, namely, 217 species, subspecies or variants in Table 4, whose sequences have been verified by publications.

[0284] Thus, the primer set allows amplification by PCR of the rrs gene of any mycobacterium present in the sample. The primer set according to the invention consists of or comprises at least three of the following primer pairs:

[0285] Pair 1:

[0286] Forward primer F1, which has the sequence: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) or a modification thereof,

[0287] Reverse primer R1 having the sequence: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2) or a modification thereof;

[0288] Pair 2:

[0289] Forward primer F3, which has the sequence: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) or a modification thereof,

[0290] Reverse primer R3, which has the sequence: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5) or a modification thereof;

[0291] Pair 3:

[0292] Forward primer F4, which has the sequence: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7) or a modification thereof,

[0293] Reverse primer R4, which has the sequence: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8) or a modification thereof.

[0294] The primer set of the present invention may comprise only these three primer pairs (i.e., a total of 6 primers), or may comprise additional primer pairs, or alternative forward primers or reverse primers. Thus, for amplifying the rrs gene of any mycobacterial origin, i.e. in an exhaustive manner, regardless of whether the mycobacterial strain is pathogenic, infects humans, or is from the tuberculosis complex, the minimum number of primers is six. This very small number of primers is particularly advantageous because it requires fewer reagents and allows simultaneous amplification with all 6 primers. Thus, the inventors have defined the minimum primer combination that allows mycobacterium-specific amplification of the rrs gene.

[0295] The inventors actually designed three primer pairs, the first primer pair corresponding to SEQ ID NO: 1 and SEQ ID NO: 2, the second primer pair corresponding to SEQ ID NO: 4 and SEQ ID NO: 5, and the third primer pair corresponding to SEQ ID NO: 7 and SEQ ID NO: 8, which allow the amplification of the rrs gene of any mycobacterial species. According to a specific embodiment, the primer set thus consists of or comprises the following three primer pairs:

[0296] Pair 1:

[0297] Forward primer F1-1, which has the sequence: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1),

[0298] Reverse primer R1-1, which has the sequence: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0299] Pair 2:

[0300] Forward primer F3-1, which has the sequence: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4),

[0301] Reverse primer R3-1, which has the sequence: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0302] Pair 3:

[0303] Forward primer F4-1, which has the sequence: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0304] Reverse primer R4-1, which has the sequence: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8).

[0305] Furthermore, the inventors have demonstrated that some modifications of the sequences of these primers do not change the properties of the primer pairs, ie they still amplify the rrs gene of the same mycobacterium, so that the three primer pairs together allow the amplification of the rrs gene of any mycobacterial species.

[0306] Therefore, the present invention also relates to the modification of SEQ ID NO: 1 and SEQ ID NO: 2 of the first primer pair, the modification of SEQ ID NO: 4 and SEQ ID NO: 5 of the second primer pair, and the modification of SEQ ID NO: 7 and SEQ ID NO: 8 of the third primer pair, the modification degree is such that the resulting three primer pairs still allow the amplification of the rrs gene of any mycobacterial species. Example 7 in the experimental part below details how to design suitable modifications of the sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8, so as to preserve exhaustiveness.

[0307] The modification is in particular the addition and / or deletion of 1 to 4 nucleotides at the 3' and / or 5' ends, and / or the substitution of 1 or 2 or 3 nucleotides. According to a particular embodiment, the deletion is a deletion of 1 to 4 nucleotides, located at the 3' end, the 5' end, or the 3' and 5' ends. The substitution is in particular the substitution of 1 or 2 nucleotides, and in particular not at the 3' and 5' ends, and in particular not at the 3' end, and more generally not in the last 5 nucleotides at the 3' end.

[0308] According to one embodiment, the modification is the addition and / or deletion of 1 to 4 nucleotides at the 3' and / or 5' end of the primer sequence.

[0309] In view of the modifications detailed above, according to different embodiments of the present invention, the first primer pair may have any one of the following sequences:

[0310] a) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0311] Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); corresponds to the first primer pair without modification, i.e., the original first primer pair,

[0312] b) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0313] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0314] c) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1);

[0315] Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12);

[0316] d) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2);

[0317] e) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-3: 5'-CACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 27);

[0318] f) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12);

[0319] g) forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); or

[0320] h) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0321] Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13).

[0322] As demonstrated in the experimental part of the present application, all of these different primer pairs allow the amplification of the same mycobacterial species as the original primer pair No. 1. Furthermore, any of these primer pairs in combination with the primer pairs corresponding to SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 8 or variants thereof allow the amplification of the sequence of the rrs gene of any mycobacterial species.

[0323] Regardless of the above, the choice of the first primer pair, in particular the selection of the sequences of the forward primer and the reverse primer of this set, is made independently of the selection of the sequences of the second and third primer pairs.

[0324] In view of the modifications detailed above, according to other independent embodiments of the present invention, the second primer pair may have any one of the following sequences:

[0325] a) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0326] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); corresponds to the unmodified second primer pair, i.e., the original second primer pair,

[0327] b) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0328] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0329] c) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0330] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0331] d) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0332] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0333] e) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0334] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0335] f) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0336] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0337] g) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0338] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17); or

[0339] h) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0340] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17).

[0341] As demonstrated in the experimental part of the present application, all of these different primer pairs allow amplification of the same mycobacterial species as the original primer pair No. 2. Furthermore, any of these primer pairs in combination with the primer pairs corresponding to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 7 and SEQ ID NO: 8 or variants thereof allow amplification of the sequence of the rrs gene of any mycobacterial species.

[0342] Regardless of the above, the choice of the second primer pair, in particular the selection of the sequences of the forward primer and the reverse primer of this set, is made independently of the selection of the sequences of the first and third primer pairs.

[0343] According to yet other independent embodiments of the present invention, the third primer pair may have any one of the following sequences:

[0344] a) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0345] Reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); corresponds to the unmodified third primer pair, i.e., the original third primer pair,

[0346] b) forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0347] c) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0348] Reverse primer R4-1: 5′-GGCATCGCAGCCCTTTG-3′ (SEQ ID NO: 8);

[0349] d) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0350] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0351] e) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0352] Reverse primer R4-5: 5′-GCATCGCAGCCCTTTGTA-3′ (SEQ ID NO: 28);

[0353] f) forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0354] g) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0355] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); or

[0356] h) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0357] Reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

[0358] As demonstrated in the examples, all of these different primer pairs allow amplification of the same mycobacterial species as the original primer pair 3. Furthermore, any of these primer pairs in combination with the primer pairs corresponding to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 5 or variants thereof allow amplification of the sequence of the rrs gene of any mycobacterial species.

[0359] Regardless of the above, the choice of the third primer pair, in particular the selection of the sequences of the forward primer and the reverse primer of this set, is made independently of the selection of the sequences of the first and second primer pairs.

[0360] Regardless of the modifications of the primer sequences mentioned above, which are modifications in the sequence that hybridizes with the target sequence to be amplified, the primers of the present invention may also contain additional sequences or one or more parts that are not directly involved in the interaction with the target sequence. The primers as disclosed may in particular contain loops required in the design of primers suitable for LAMP (loop-mediated isothermal amplification) technology. Therefore, the primer sequences as disclosed in this specification relate to sequences that hybridize with the target mycobacterium sequence.

[0361] The three primer pairs disclosed above allow amplification of sequences of the rrs gene from any mycobacterial species, i.e., regardless of the mycobacterial species, subspecies or variants. The three primer pairs do not target the same part of the rrs gene; they target sequences in the rrs gene that are conserved between different mycobacterial species or between subgroups of mycobacteria. Therefore, the rrs gene of any mycobacterial species will be targeted by at least one primer pair of the primer set of the present invention, producing an amplified product. However, the rrs gene of some mycobacterial species can be targeted by 2 primer pairs of the group of the present invention. Therefore, the rrs gene of any mycobacterial species will hybridize with at least one primer pair in the primer set according to the present invention, but not necessarily with only one primer pair.

[0362] The absence of amplification in a sample comprising DNA extracted from bacteria when the set of 3 primer pairs of the invention is used under appropriate conditions means that the sample does not comprise a sequence corresponding to the rrs gene of a Mycobacterium species and therefore the sample does not comprise any species of Mycobacterium.

[0363] In another aspect, the present invention relates to a kit for amplifying the sequence of the Mycobacterium rrs gene in a sample by PCR. Such a kit comprises a primer set as disclosed above, i.e. at least 3 primer pairs as disclosed above.

[0364] Different amplification methods based on polymerase chain reaction (PCR) can be used together with the kit of the present invention in combination with appropriate detection methods. However, the conditions of the amplification cycles and the detection methods can vary depending on the amplification method selected. The technician will know how to adjust such conditions.

[0365] The amplification technique may in particular be the LAMP (loop-mediated isothermal amplification) technique.

[0366] Another technique that is particularly suitable in the context of the present invention is amplification by qPCR (quantitative PCR, also called real-time PCR). Quantitative PCR (or qPCR) is based on PCR and is suitable for amplifying short sequences and detecting in real time. This technique is particularly suitable in the context of the present invention insofar as the rrs sequences amplified by the primer pairs disclosed in the present application are in fact short sequences. In the context of the present invention, this technique can be used to detect the amplification (or absence of amplification) of a sequence, or for quantification of the amplification product.

[0367] Regarding the detection of amplification products by qPCR, different techniques can be used.

[0368] One of such techniques is the use of a DNA intercalator (such as SYBR Green). It non-specifically inserts into the minor groove of a double-stranded DNA structure and emits fluorescence. Therefore, an increase in the fluorescent signal indicates an increase in the number of amplified sequences, and thus indicates the presence of the target sequence.

[0369] Another approach to detecting amplification is based on hydrolysis probes (e.g. The technique of qPCR (qPCR probe) uses a dual-labeled probe with a sequence complementary to the amplified target sequence. The probe is coupled to a fluorophore and a quencher. As long as the fluorophore and the quencher are in proximity, the fluorescent signal of the fluorophore is quenched. During the hybridization step of qPCR, the primers and probes hybridize to the target sequence. During the extension period, due to the 5'-3' exonuclease activity of the polymerase; the probe is degraded, releasing the fluorophore, thereby alleviating the quenching effect of the quencher and allowing the fluorophore to fluoresce.

[0370] The use of hydrolysis probes generally increases the specificity of quantitative PCR.

[0371] Sequences of probes suitable for use in the present invention are disclosed below.

[0372] Amplification can also be performed by digital PCR or dPCR. dPCR is a technique that provides absolute quantification of nucleic acid target sequences; it is an end-point measurement that enables quantification of nucleic acids without the use of a standard curve. The PCR reaction mixture is distributed among thousands of independent reactions. Each reaction is analyzed by specific software to determine whether it is positive or negative. Based on Poisson's statistical law, an absolute quantification of the initial copy number / μL is provided.

[0373] Detection can be performed using hydrolysis probes or via intercalating agents such as EvaGreen.

[0374] The main advantage of this technique is that there is no reference scale, as quantification is absolute.

[0375] Test kit of the present invention can advantageously comprise other components, especially by the necessary components of PCR amplification, such as polymerase (particularly DNA polymerase) and deoxyribonucleoside triphosphates.This list is not exhaustive.According to a preferred embodiment, the polymerase is Taq polymerase.Many other suitable polymerases are well known to the technician and are not described in detail here.They will depend on the selected amplification method.

[0376] According to one embodiment, the kit according to the invention does not comprise any other primers than the three primer pairs disclosed above; or does not comprise any other primers or any other primer pairs hybridizing to mycobacterial sequences.

[0377] According to another embodiment, the kit of the present invention may comprise additional primers. Advantageously, the kit may actually comprise another primer pair (i.e., a forward primer and a reverse primer) suitable for amplifying a nucleic acid sequence used as a control. This nucleic acid sequence used as an exogenous control is added to the sample at a defined concentration; or this nucleic acid sequence used as an endogenous control is present in the sample at a defined concentration. The exogenous control may be any DNA sequence that has been extracted or is present in a microorganism and is unrelated to the mycobacterium to be detected. The endogenous control may be any DNA sequence that is known to be present in the sample and is unrelated to the mycobacterium to be detected, for example, in the test of a cell bank, the endogenous control may be a DNA sequence of a gene from a cell that is not present in the mycobacterium genome.

[0378] According to another embodiment, a nucleic acid control is part of a kit of the invention and is added in a defined concentration to the sample to be tested.

[0379] In addition, the kit may also contain additional primers for detecting other contaminants besides mycobacteria; in particular, detecting harmful or infectious agents, such as viruses, bacteria, fungi. In order to incorporate these potential additional primers, an important advantage of the present invention is therefore that only 3 primer pairs are designed for the amplification of the entire Mycobacteriaceae family.

[0380] In a particular embodiment, the kit according to the invention comprises not only a primer set for amplifying the sequence of a Mycobacterium species, if present in the sample, but also a probe to detect one or more amplification products, if present.

[0381] According to such an embodiment, the kit of the present invention advantageously comprises a probe S1 having the sequence 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3) or a modification thereof for detecting the sequence amplified by the forward primer F1 and the reverse primer R1 of the first primer pair disclosed above.

[0382] In a specific embodiment, the kit of the present invention further comprises a probe S3 having the sequence: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6) or a modification thereof, for detecting the sequence amplified by the forward primer F3 and the reverse primer R3 of the second primer pair disclosed above.

[0383] In a specific embodiment, the kit of the present invention further comprises a probe S4 having the sequence: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) or a modification thereof, for detecting the sequence amplified by the forward primer F4 and the reverse primer R4 of the third primer pair disclosed above.

[0384] The inventors of the present invention have actually shown in the Examples section that probes having SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 9 are suitable for detecting amplification products obtained by amplification with the first primer pair, the second primer pair and the third primer pair, respectively, wherein the primers have the original primer design or have modified sequences as described in detail.

[0385] Furthermore, they have demonstrated that modification of the sequences of these probes can still preserve the ability to detect amplification products obtained by amplification with the first primer pair, the second primer pair, and the third primer pair according to the present invention.

[0386] Modification of the probe is, for example, the addition and / or deletion of 1 to 3 nucleotides, in particular only one or two nucleotides, at the 3' end and / or at the 5' end of the probe.

[0387] When using the primers of the invention for amplifying a sequence corresponding to the rrs gene of a Mycobacterium species, the probe as defined above has a length that is fully compatible with the length of the expected amplification product.

[0388] In view of the modifications detailed above, according to various embodiments of the present invention, the first probe S1 may have any one of the following sequences:

[0389] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), corresponding to the unmodified original design,

[0390] Probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and

[0391] Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23).

[0392] According to other independent embodiments, probe S3 is selected from:

[0393] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), corresponding to the unmodified original design,

[0394] Probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and

[0395] Probe S3-2: 5'-CGGTTCCCTTGTGGC-3' (SEQ ID NO: 25).

[0396] According to yet other independent embodiments, probe S4 is selected from:

[0397] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO:9), corresponding to the unmodified original design, and

[0398] Probe S4-1: 5'-ACATGCTACAATGGCCGGT-3' (SEQ ID NO: 26).

[0399] Depending on the specific combination, probe S1-0 is used in combination with any of the following primer pairs: F1-1 (SEQ ID NO: 1) and R1-1 (SEQ ID NO: 2); F1-1 and R1-6 (SEQ ID NO: 13); F1-1 and R1-5 (SEQ ID NO: 12); F1-2 (SEQ ID NO: 10) and R1-1; F1-2 and R1-3 (SEQ ID NO: 27); F1-2 and R1-5; F1-2 and R1-6; and F1-3 (SEQ ID NO: 11) and R1-6.

[0400] According to other combinations, probe S1-1 is used in combination with any of the following primer pairs: F1-1 and R1-1; F1-1 and R1-6; F1-1 and R1-5; F1-2 and R1-1; and F1-3 and R1-6.

[0401] According to still other combinations, probe S1-2 is used in combination with any of the following primer pairs: F1-1 and R1-1; F1-1 and R1-6; F1-1 and R1-5; F1-2 and R1-1; F1-2 and R1-5; and F1-3 and R1-6.

[0402] Depending on the specific combination, probe S3-0 is used in combination with any of the following primer pairs: F3-1 (SEQ ID NO:4) and R3-1 (SEQ ID NO:5); F3-3 (SEQ ID NO:14) and R3-1; F3-1 and R3-2 (SEQ ID NO:15); F3-1 and R3-3 (SEQ ID NO:16); F3-1 and R3-4 (SEQ ID NO:17); F3-3 and R3-2; F3-3 and R3-3; and F3-3 and R3-4.

[0403] According to other combinations, probe S3-1 is used in combination with any of the following primer pairs: F3-1 and R3-1; F3-3 and R3-1; F3-1 and R3-2; F3-3 and R3-2; and F3-3 and R3-3.

[0404] According to still other combinations, probe S3-2 is used in combination with any of the following primer pairs: F3-1 and R3-1; F3-3 and R3-1; F3-1 and R3-2; F3-1 and R3-3; F3-3 and R3-3; and F3-3 and R3-4.

[0405] Depending on the specific combination, probe S4-0 is used in combination with any of the following primer pairs: F4-1 (SEQ ID NO:7) and R4-1 (SEQ ID NO:8); F4-3 (SEQ ID NO:18) and R4-1; F4-5 (SEQ ID NO:19) and R4-1; F4-1 and R4-3 (SEQ ID NO:20); F4-1 and R4-5 (SEQ ID NO:28); F4-3 and R4-3; F4-5 and R4-3; and F4-5 and R4-6 (SEQ ID NO:21).

[0406] According to other combinations, probe S4-1 is used in combination with any of the following primer pairs: F4-1 and R4-1; F4-3 and R4-1; F4-5 and R4-1; F4-1 and R4-3; F4-3 and R4-3; F4-5 and R4-3; and F4-5 and R4-6.

[0407] In one embodiment, the kit comprises a forward primer F1-1 (SEQ ID NO: 1), a reverse primer R1-1 (SEQ ID NO: 2), and a probe S1-0 (SEQ ID NO: 3).

[0408] In another embodiment, the kit comprises a forward primer F3-1 (SEQ ID NO: 4), a reverse primer R3-1 (SEQ ID NO: 5), and a probe S3-0 (SEQ ID NO: 6).

[0409] In yet another embodiment, the kit comprises a forward primer F4-1 (SEQ ID NO: 7), a reverse primer R4-1 (SEQ ID NO: 8), and a probe S4-0 (SEQ ID NO: 9).

[0410] According to certain embodiments, the kit comprises F1-1, R1-1, S1-0, F3-1, R3-1, S3-0, F4-1, R4-1, and S4-0.

[0411] The inventors have in fact demonstrated that the combination of primer pairs and associated probes as disclosed herein not only allows the amplification of the sequence of the rrs gene of any mycobacterial species, but also allows the detection of sequences of mycobacterial species only, without detecting sequences of any other bacterial origin. Therefore, the kit of the invention with a combination of specific primer pairs and corresponding probes not only provides exhaustiveness of mycobacterial detection, but also provides specificity of such detection relative to other bacteria. Therefore, the kit of the invention with corresponding probes is a kit for detecting mycobacterial species that provides exhaustiveness and specificity.

[0412] The kit of the present invention may also comprise a probe designed to detect a sequence amplified from a nucleic acid control by another primer pair disclosed above.

[0413] The kit of the invention with at least 3 primer pairs and the associated probes disclosed is particularly suitable for amplification by qPCR or by dPCR. Detection can be performed with the probes to confer specificity for mycobacterial detection.

[0414] The probe of test kit of the present invention is advantageously directly or indirectly connected to mark.Such mark can be any kind of mark, especially any kind of fluorophore label, it is suitable for detecting probe and is suitable for thermal cycler.Specific mark is dyestuff or fluorophore label.The specific label thing illustrated in the embodiment is 6-carboxyfluorescein (6-FAM or FAM).Several other labels or fluorophores well known to those skilled in the art and which can be used are for example Cy3 dyestuff, Cy5 dyestuff, VIC, YAK (Yakima Yellow), Red, HEX, TET, cyan dye etc.

[0415] In specific embodiments, the probe is also linked, directly or indirectly, to a quencher to function as a hydrolysis probe.

[0416] According to other embodiments, when the kit comprises the probes S1, S3 and S4 detailed above, the three probes are directly or indirectly linked to the same label, such as a fluorophore label. In fact, insofar as the kit allows the exhaustive and selective amplification of the sequence of the rrs gene of any mycobacterial species, the detection of the amplification product by the probes indicates the presence of mycobacterial sequences in the sample; whether the amplification product is detected by the probes S1, S3 and S4 is not necessarily informative. In this regard, it is to be reminded that a given rrs gene of a mycobacterial species can additionally be amplified and detected by more than one combination of primers and probes.

[0417] When the kit further comprises a primer pair for amplifying a nucleic acid control and a probe for detecting the corresponding amplification product, the probe for the nucleic acid control may also be directly or indirectly linked to a label, which is advantageously a label different from that of the probes S1, S3 and S4. In this way, the amplification obtained by the control system can be immediately distinguished from the amplification obtained due to the presence of the rrs gene sequence of mycobacterium origin. A quencher is also linked to the probe for the control.

[0418] The kit as disclosed is for samples that may contain mycobacterial DNA from mycobacteria, in particular samples obtained after DNA extraction. In the sample, the mycobacterial DNA must be freely accessible (i.e. not trapped inside the cell, not fragmented) and correspond to whole DNA; i.e. DNA extracted from live mycobacteria according to a protocol that does not damage the DNA. Controls for DNA extraction can be added when appropriate and can be part of the kit.

[0419] The kit according to the invention comprising a specific combination of primer sets and corresponding probes as disclosed allows the detection of an amplification product with any one of the probes S1, S3 and S4 to indicate the specific presence in the sample of DNA of at least one mycobacterium species, more particularly of at least one of the 217 different species or subspecies or variants of mycobacteria known to date, regardless of their classification.

[0420] In contrast, due to the exhaustiveness conferred by the primer set of the kit, the absence of detection of an amplification product when using the kit of the present invention indicates the absence of DNA of any species of mycobacterium in the sample, i.e., the absence of the target sequence to be amplified. According to a specific embodiment, an internal control is added to the kit to ensure that the lack of amplification and detection is actually due to the absence of the target sequence.

[0421] For example, an internal control is added to the sample during the extraction step. It allows to control this extraction step and, in case of no amplification of mycobacteria, it ensures that this is not due to a defective extraction step.

[0422] According to yet another embodiment, a kit according to the invention comprises polymerase chain reaction reagents and a set of at least 3 primer pairs according to the invention; with or without associated probes, and potentially also a DNA extraction kit.

[0423] In another aspect, the present invention relates to different methods for amplifying and detecting the sequence of the rrs gene of any mycobacterium using the kit of the present invention as described in the preceding section. In fact, given the exhaustiveness of the primer combinations and the sensitivity of the PCR technique, the present invention provides a highly sensitive detection test for mycobacteria, suitable for several fields, and in particular for detecting mycobacteria in samples with very low mycobacterium content (e.g., less than 100 live mycobacteria / mL, even less than 10 live mycobacteria / mL, or even about 5 or 1 live mycobacteria / mL).

[0424] The present invention particularly relates to a method for amplifying and detecting the sequence of the rrs gene of any mycobacterium present in a sample, the method comprising the following steps:

[0425] a) performing in vitro PCR on nucleic acids extracted from said sample using a set of at least three primer pairs as disclosed above, and

[0426] b) Detecting the presence or absence of the amplified product.

[0427] Depending on the method used for amplification by PCR, it is quite obvious that these two steps can be performed simultaneously or sequentially. As explained above, techniques such as qPCR allow in fact simultaneous amplification and detection of the amplification products.

[0428] The amplification step can be performed with only three primer pairs, in particular the first, second and third pairs of the invention, without additional primers hybridizing to mycobacterial sequences. Such an embodiment does not exclude the amplification with a nucleic acid control, performed with a primer pair specific for this control and which is not related to mycobacterial sequences (internal control). According to such an embodiment, the amplification step a) is performed with an additional control primer pair comprising a forward primer and a reverse primer, which is designed for the amplification of a nucleic acid control present in or added to the sample; such a nucleic acid control is not related to any mycobacterial sequence and is not amplified by the three primer pairs of the invention.

[0429] According to a particular embodiment, the three primer pairs comprise or consist of the following primers:

[0430] Pair 1:

[0431] Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0432] Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2)

[0433] Pair 2:

[0434] Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0435] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5)

[0436] Pair 3:

[0437] Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7)

[0438] Reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8).

[0439] Primers with modified sequences with respect to F1-1, F3-1, F4-1, R1-1, R3-1 and R4-1 are also suitable for use in the methods of the invention. Suitable modifications have been extensively discussed in conjunction with the primer sets of the invention and are similarly applicable to this aspect of the invention.

[0440] As disclosed in the previous aspects in conjunction with the primer sets of the present invention, different primer pairs may also be independently selected in:

[0441] - For pair 1, in the list of primer pairs consisting of: F1-1 (SEQ ID NO: 1) and R1-1 (SEQ ID NO: 2); F1-1 and R1-6 (SEQ ID NO: 13); F1-1 and R1-5 (SEQ ID NO: 12); F1-2 (SEQ ID NO: 10) and R1-1; F1-2 and R1-3 (SEQ ID NO: 27); F1-2 and R1-5; F1-2 and R1-6; and F1-3 (SEQ ID NO: 11) and R1-6;

[0442] - for pair 2, in the list of primer pairs consisting of: F3-1 (SEQ ID NO:4) and R3-1 (SEQ ID NO:5); F3-3 (SEQ ID NO:14) and R3-1; F3-1 and R3-2 (SEQ ID NO:15); F3-1 and R3-3 (SEQ ID NO:16); F3-3 and R3-2; F3-3 and R3-3; F3-1 and R3-4 (SEQ ID NO:17); and F3-3 and R3-4; and

[0443] -For pair 3, in the list of primer pairs consisting of: F4-1 (SEQ ID NO:7) and R4-1 (SEQ ID NO:8); F4-3 (SEQ ID NO:18) and R4-1; F4-5 (SEQ ID NO:19) and R4-1; F4-1 and R4-3 (SEQ ID NO:20); F4-1 and R4-5 (SEQ ID NO:28); F4-3 and R4-3; F4-5 and R4-3; and F4-5 and R4-6 (SEQ ID NO:21).

[0444] According to the method of the present invention, the absence of detection of an amplification product indicates the absence of any species of Mycobacterium in the sample, or at least any one of the 217 species, subspecies and variants of Table 4, in terms of the primer set used in the method giving exhaustiveness to the method, i.e., regardless of the Mycobacterium species that may be present in the sample, its rrs gene will be amplified by at least one primer pair.

[0445] Furthermore, as detailed in conjunction with the kit of the invention, the amplification step a) can be performed by any suitable PCR method, but very suitable methods according to the invention are quantitative PCR and digital PCR. Quantitative PCR is described in the Examples section of the present application; similar results are obtained by dPCR.

[0446] As is apparent from the foregoing, the method of the invention does not require any cultivation step of the mycobacteria. Once the nucleic acid has been extracted from the sample to be tested, the method can be performed directly on the sample, without any cultivation. The method is therefore particularly rapid, especially relative to methods based on mycobacterial cultivation; the time to obtain a result can actually be reduced by more than 90%, in particular 96%. The method is also faster than methods that require a pre-cultivation step of the mycobacteria before amplification. The claimed method does not require any cultivation step at all. The method also presents the advantage of being able to detect any and all mycobacteria, including fastidious and intracellular mycobacterium species.

[0447] According to a specific embodiment, the amplifications with the three primer pairs are carried out simultaneously in the same reaction mixture, i.e. triple amplification. In addition, when another primer pair is also added, for example designed for the amplification of a nucleic acid control present in or added to the sample, the amplifications with the other primer pairs are also advantageously carried out simultaneously, i.e. quadruple amplification. The inventors have actually demonstrated in Example 5 that such quadruple amplification is possible without negative interactions, thus preserving the exhaustiveness and specificity of the detection method and improving its efficiency when using appropriate probes.

[0448] The amplification step a) of the method of the invention is carried out under conditions appropriate for amplification and in the presence of all appropriate components necessary for the chosen amplification technique (ie using appropriate deoxyribonucleoside triphosphates and a polymerase).

[0449] Regarding step b) of detection, this step can be performed with the relevant probes corresponding to the primer pairs, as already disclosed in connection with the kit of the present invention. In this respect, the detection is advantageously performed with: probe S1 having the sequence 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3) or a modification thereof, for detecting the sequence amplified by the primers F1 and R1; probe S3 having the sequence: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6) or a modification thereof, for detecting the sequence amplified by the primers F3 and R3; and probe S4 having the sequence: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) or a modification thereof, for detecting the sequence amplified by the primers F4 and R4. Suitable modifications have been detailed in the previous section and are applicable to this aspect of the present invention.

[0450] According to a particular embodiment, the probe is selected from:

[0451] - For the probe S1, selected from:

[0452] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3),

[0453] Probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and

[0454] Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23);

[0455] Wherein when probe S1 is S1-0, the first primer pair is selected from:

[0456] a) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0457] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0458] b) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0459] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0460] c) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0461] Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12);

[0462] d) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10)

[0463] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0464] e) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-3: 5'-CACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 27);

[0465] f) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12);

[0466] g) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10)

[0467] Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); and

[0468] h) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0469] Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13), wherein when the probe S1 is S1-1, the first primer pair is selected from:

[0470] a) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0471] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0472] b) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0473] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0474] c) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0475] Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12);

[0476] d) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10)

[0477] Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); and

[0478] e) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0479] Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13), wherein when probe S1 is S1-2, the first primer pair is selected from:

[0480] a) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0481] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0482] b) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0483] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0484] c) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0485] Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12);

[0486] d) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2);

[0487] e) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10)

[0488] Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); and

[0489] f) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0490] Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13).

[0491] - For the probe S3, selected from:

[0492] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6),

[0493] Probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and

[0494] Probe S3-2: 5′-CGGTTCCCTTGTGGC-3′ (SEQ ID NO: 25);

[0495] Wherein when probe S3 is S3-0, the second primer pair is selected from:

[0496] a) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0497] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0498] b) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0499] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0500] c) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0501] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0502] d) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0503] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0504] e) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0505] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0506] f) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0507] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0508] g) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0509] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17); and

[0510] h) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0511] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17),

[0512] Wherein when the probe S3 is S3-1, the second primer pair is selected from:

[0513] a) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0514] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0515] b) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0516] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0517] c) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0518] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0519] d) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0520] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); and

[0521] e) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0522] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16), wherein when probe S3 is S3-2, the second primer pair is selected from:

[0523] a) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0524] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0525] b) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0526] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0527] c) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0528] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0529] d) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0530] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0531] e) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0532] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17). And

[0533] f) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0534] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16).

[0535] - For the probe S4, selected from:

[0536] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and

[0537] Probe S4-1: 5′-ACATGCTACAATGGCCGGT-3′ (SEQ ID NO: 26);

[0538] Wherein when probe S4 is S4-0, the third primer pair is selected from:

[0539] a) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0540] b) forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0541] c) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0542] Reverse primer R4-1: 5′-GGCATCGCAGCCCTTTG-3′ (SEQ ID NO: 8);

[0543] d) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0544] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0545] e) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0546] Reverse primer R4-5: 5′-GCATCGCAGCCCTTTGTA-3′ (SEQ ID NO: 28);

[0547] f) forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0548] g) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0549] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); and

[0550] h) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0551] Reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21),

[0552] Wherein when the probe S4 is S4-1, the third primer pair is selected from:

[0553] i. Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0554] Reverse primer R4-1: 5′-GGCATCGCAGCCCTTTG-3′ (SEQ ID NO: 8);

[0555] ii. Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0556] iii. Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0557] Reverse primer R4-1: 5′-GGCATCGCAGCCCTTTG-3′ (SEQ ID NO: 8);

[0558] iv. Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7),

[0559] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0560] v. Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0561] vi. Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0562] Reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); and

[0563] vii. Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19),

[0564] Reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

[0565] In one embodiment, the method is performed using forward primer F1-1 (SEQ ID NO: 1), reverse primer R1-1 (SEQ ID NO: 2), and probe S1-0 (SEQ ID NO: 3).

[0566] In another embodiment, the method is performed using forward primer F3-1 (SEQ ID NO: 4), reverse primer R3-1 (SEQ ID NO: 5), and probe S3-0 (SEQ ID NO: 6).

[0567] In yet another embodiment, the method is performed using forward primer F4-1 (SEQ ID NO: 7), reverse primer R4-1 (SEQ ID NO: 8), and probe S4-0 (SEQ ID NO: 9).

[0568] According to certain embodiments, the method is performed with F1-1, R1-1, S1-0, F3-1, R3-1, S3-0, F4-1, R4-1 and S4-0.

[0569] The detection step b) of the method may also be performed by using a DNA intercalator such as SYBR Green as detailed above. However, in order to confer specificity, in a particular embodiment, the detection is performed with a probe as disclosed above.

[0570] When probes are used to detect potential amplification products, according to a specific embodiment, the amplification step a) and the detection step b) are carried out in a single reaction mixture comprising different primer pairs (i.e., F1, R1, F3, R3, F4 and R4) and the associated probes S1, S3 and S4. The inventors have in fact demonstrated that simultaneous amplification and detection using three primer pairs and the associated three probes gives satisfactory results.

[0571] In addition, they have shown that amplification and detection can also be performed simultaneously using additional primer pairs and associated probes, particularly primers and probes specifically designed for amplification and detection of nucleic acid controls. Therefore, the method of the present invention can also include additional primer pairs and associated probes designed to detect nucleic acid controls present in or added to the sample.

[0572] As detailed in conjunction with the kit of the invention, the probe may be directly or indirectly linked to a label (such as a dye or fluorophore label). Suitable labels are described in the Examples and include 6-FAM.

[0573] In addition, all specific embodiments disclosed in conjunction with the kit of the present invention are fully applicable to this aspect of the present invention related to the method. In this regard, as already described in detail, probes S1, S3 and S4 are directly or indirectly connected to the same label, and the probes of the control system are directly or indirectly connected to different labels. The potential reasons for this selection have been disclosed.

[0574] As described in detail above, the amplification and detection steps can be performed simultaneously or sequentially. Before performing step b), or before the readout corresponding to step b), step a) can also include at least several amplification cycles performed by PCR. In particular, there are at least 30 PCR cycles, such as at least 35 cycles; for example about 37 cycles, in particular at least or about 40 cycles. The technician can easily determine the appropriate number of cycles according to the experimental conditions to distinguish the specific amplification of mycobacterial nucleic acids from the non-specific amplification or noise of non-mycobacterial nucleic acids. The determination of the appropriate threshold value of the number of PCR cycles is particularly illustrated in Example 8.

[0575] The method according to the invention can be advantageously used for different types of samples. The sample can actually be, for example, a biopharmaceutical sample that may be contaminated by mycobacteria (for example, due to the use of eukaryotic cells in its production process); or the sample can also be an environmental sample, for example, a water sample from an installation; the sample can also be a biological sample obtained from an animal or human that may be contaminated by mycobacteria. The sample can also be a culture medium for cell culture, or a matrix for producing a drug product, a virus seed, a starting material for cell culture, a cell culture or its supernatant, an intermediate product (such as a crude harvest of a bulk drug), a prepared drug product or a final product. The sample can come from any step of any drug product production, such as, for example, CHO cells for the production of recombinant proteins (for example, cytomegalovirus protein antigens), a crude harvest of a bulk drug from MRC5 cells (for example, for virus production, such as HAV (hepatitis A virus)), a crude harvest of a bulk drug from Vero cells (for example, for virus production, such as yellow fever virus or rabies virus). The inventors have actually demonstrated that specific and exhaustive amplification of any possible mycobacteria in these matrices can be performed according to the method of the invention.

[0576] In a particular embodiment, the method is performed on a biopharmaceutical sample from a medicament or vaccine at any step in the production of the drug product, in particular on the final product, on any intermediate matrix, on virus seeds or on starting material such as cell cultures or culture media.

[0577] By the method of the present invention, detection of an amplification product using any one of probes S1, S3 and S4 indicates the specific presence of at least one mycobacterium species in the sample among at least 200 different mycobacteria, more particularly 217 species, subspecies and variants of mycobacteria.

[0578] Depending on the expected concentration of mycobacterial DNA and according to the user manual recommendations of the PCR mix provider, the skilled person will adjust the concentrations of the different primers F1, R1, F3, R3, F4 and R4. In the case of biopharmaceutical samples and detection by qPCR, the concentrations to be used are typically in the range between 100 nM and 400 nM for the primers in the reaction mixture.

[0579] Similarly, the concentration of the probes will be adjusted depending, inter alia, on the expected concentration of mycobacterial DNA, the number of PCR amplification cycles prior to detection, and the type of detection technique. In the case of biopharmaceutical samples and detection by qPCR, probes S1, S3 and S4 are typically added at concentrations ranging between 50 nM and 250 nM.

[0580] According to a specific embodiment, step a) and b) are carried out simultaneously in the same reaction mixture. Thus the DNA extract of the sample is contacted with three primer pairs and 3 kinds of related probes in the same reaction mixture simultaneously. As described in detail above, the 4th primer pair and related probe for amplification control sequence are also advantageously added, and are still added in the same reaction mixture. Thus three or four different primer pairs and related probes are added to the DNA extract, and amplification and detection are carried out in this single reaction mixture. The inventors have actually proved that quadruple reaction is possible, and does not lose the detailedness and specificity of detection, even in the presence of related probes. For triple or quadruple amplification and detection, PCR technology is such as qPCR or dPCR, and especially qPCR.

[0581] Performing amplification and detection in triplicate or quadruplex is a major time gain and also allows savings in materials, reagents, machine time and costs.

[0582] The inventors have also demonstrated that the method disclosed above can detect very small amounts of mycobacterium species, and is therefore a highly sensitive method suitable for the pharmaceutical field. For most strains, the method can actually detect mycobacterium DNA at a concentration lower than 10 fg / μL, lower than 1 fg / μL, and even lower than 0.3 fg / μL, and generally lower than 0.03 fg / μL. Therefore, by adjusting the DNA extraction step, mycobacteria can be detected with a sensitivity substantially similar to or superior to the sensitivity of the pharmacopoeia method, thereby meeting the requirements of European Pharmacopoeia 2.6.2 for mycobacterium detection. The present invention provides a highly sensitive mycobacterium detection test suitable for several fields, particularly for detecting mycobacteria in samples with very low mycobacterium content (e.g., lower than 100 live mycobacteria / mL, even lower than 10 live mycobacteria / mL, or even about 5 or 1 live mycobacteria / mL).

[0583] Thus, the method is advantageously an alternative to pharmacopeia methods and furthermore can be performed in less than 48 hours, and even in less than 24 hours.

[0584] Therefore, the method is very valuable for biopharmaceutical product testing, especially for vaccine testing, because this method can replace the pharmacopoeial method with the same or even increased sensitivity and comparable or increased specificity (see Example 8.1) and has a wider detection range.

[0585] According to yet another aspect, the present invention also relates to the use of the primer set detailed according to the previous aspect, or the use of the kit also detailed, which is used to amplify the mycobacterium rrs gene sequence present in the sample by PCR. It is very obvious that all potential or specific embodiments disclosed about the primer set and kit of the present invention also apply to this other aspect. In this regard, suitable primer pairs have been disclosed and are also applicable to this aspect; the same is true for related probes. Similarly, different PCR techniques that can be used have been described in detail in conjunction with the previous aspects; specific techniques are qPCR and dPCR, especially qPCR. If suitable probes for detection are present in the kit, the use of the kit of the present invention can be for amplifying and detecting the mycobacterium rrs gene sequence present in the sample.

[0586] The use according to the invention results in an exhaustive amplification of any mycobacterial rrs gene that may be present in the sample. Furthermore, by using the kit of the invention with the relevant probes, the use results in the specific detection of mycobacterial rrs genes, and other bacterial rrs genes that may be present in the sample are not detected.

[0587] Such use according to the invention may be in vivo, ex vivo or in vitro; but in particular in vitro. Furthermore, the use is carried out on a sample.

[0588] According to a specific embodiment, the present invention relates to the in vitro use of at least three of the following primer pairs and associated probes:

[0589] System 1:

[0590] Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0591] Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2)

[0592] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3)

[0593] System 3:

[0594] Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4)

[0595] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5)

[0596] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6)

[0597] System 4:

[0598] Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7)

[0599] Reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8)

[0600] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9),

[0601] Used to specifically amplify and detect mycobacterial nucleic acids present in a sample by PCR without amplifying other bacterial nucleic acids.

[0602] In certain embodiments, only the three disclosed primer pairs and related probes are used, potentially in combination with other probes or primers not related to mycobacterial species.

[0603] In different uses according to the invention, the primers and probes of the three systems are advantageously used simultaneously, ie in a single amplification step. In these uses, a fourth system related to amplification and detection of control nucleic acid molecules can also be combined with the first three systems.

[0604] As for other aspects of the invention, the PCR technique may be any suitable technique, but is for example qPCR or dPCR, and in particular qPCR.

[0605] According to another specific embodiment, the present invention also relates to a method for detecting the presence of mycobacterial contamination in a pharmaceutical product (e.g., in a vaccine) without any mycobacterial culture step, the method comprising the following steps:

[0606] a) amplifying in vitro nucleic acid extracted from a sample of the product by quantitative PCR (qPCR) or dPCR using the first, second and third primer pairs described above that hybridize to the rrs gene;

[0607] b) Detecting the presence or absence of the amplified product by the following probes:

[0608] i) a probe S1 for detecting the sequence amplified by the first primer set, which is selected from:

[0609] Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3),

[0610] Probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and

[0611] Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23);

[0612] Wherein when the probe S1 is S1-1, the first primer pair is selected from:

[0613] 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0614] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0615] 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0616] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0617] 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0618] Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID

[0619] NO:12);

[0620] 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID

[0621] NO:10)

[0622] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0623] as well as

[0624] 5) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0625] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0626] When the probe S1 is S1-2, the first primer pair is selected from:

[0627] 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0628] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0629] 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0630] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0631] 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1)

[0632] Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID

[0633] NO:12);

[0634] 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10)

[0635] Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2);

[0636] 5) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10)

[0637] Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12);

[0638] as well as

[0639] 6) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11)

[0640] Reverse primer R1-6: 5′-GGATCCCAAGGAAGGAAACC-3′ (SEQ ID NO: 13);

[0641] ii) a probe S3 for detecting the sequence amplified by the second primer set, which is selected from:

[0642] Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6),

[0643] Probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and

[0644] Probe S3-2: 5′-CGGTTCCCTTGTGGC-3′ (SEQ ID NO: 25);

[0645] Wherein when the probe S3 is S3-1, the second primer pair is selected from:

[0646] 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0647] 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0648] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0649] 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0650] 4) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0651] Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0652] as well as

[0653] 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0654] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); when the probe S3 is S3-2, the second primer pair is selected from:

[0655] 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0656] 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0657] Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5);

[0658] 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15);

[0659] 4) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0660] 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0661] Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17);

[0662] as well as

[0663] 6) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14)

[0664] Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16);

[0665] iii) a probe S4 for detecting the sequence amplified by the third primer set, which is selected from:

[0666] Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and

[0667] Probe S4-1: 5′-ACATGCTACAATGGCCGGT-3′ (SEQ ID NO: 26);

[0668] Wherein when the probe S4 is S4-1, the third primer pair is selected from:

[0669] 1) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0670] 2) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0671] 3) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8);

[0672] 4) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0673] 5) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0674] 6) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20);

[0675] as well as

[0676] 7) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

[0677] The steps may be performed sequentially or simultaneously, such as partially simultaneously.

[0678] The first primer pair is, for example, F1-1 and R1-1. In this case, the first probe may be any one of S1-0, S1-1, and S1-2.

[0679] The second primer pair is, for example, F3-1 and R3-1. In this case, the second probe may be any one of S3-0, S3-1, and S3-2.

[0680] The third primer pair is, for example, F4-1 and R4-1. In this case, the third probe may be any one of S4-0 and S4-1.

[0681] Probe S1 can be S1-0; in this case, the first primer pair is selected from F1-1 and R1-1; F1-1 and R1-6; F1-1 and R1-5, F1-2 and R1-1; F1-2 and R1-3; F1-2 and R1-5; F1-2 and R1-6; and F1-3 and R1-6.

[0682] Probe S3 can be S3-0; in this case, the second primer pair is selected from F3-1 and R3-1; F3-3 and R3-1; F3-1 and R3-2; F3-1 and R3-3; F3-1 and R3-4; F3-3 and R3-2; F3-3 and R3-3; and F3-3 and R3-4.

[0683] Probe S4 can be S4-0; in this case, the third primer pair is selected from F4-1 and R4-1; F4-3 and R4-1; F4-5 and R4-1; F4-1 and R4-3; F4-1 and R4-5; F4-3 and R4-3; F4-5 and R4-3; and F4-5 and R4-6.

[0684] In a particular embodiment, the first primer pair is F1-1 and R1-1, and the associated probe is S1-0; the second primer pair is F3-1 and R3-1, and the associated probe is S3-0; and the third primer pair is F4-1 and R4-1, and the associated probe is S4-0.

[0685] In the experimental part, the inventors have indeed demonstrated that the specificity and sensitivity of the method, primers and probes are not lost in the presence of a biopharmaceutical matrix such as cell supernatant, crude harvest of drug substance or culture medium (see in particular Examples 8 and 9).

[0686] According to a particular embodiment of this particular method, a fourth primer pair and associated probe are added to amplify an exogenous nucleic acid molecule used as a control. Thus, this fourth primer pair and associated probe is a control system to be used in combination with the three systems providing amplification and detection of the Mycobacterium rrs gene.

[0687] Three primer pairs and associated probes hybridizing to the rrs gene and a fourth primer pair and associated probe hybridizing to a control molecule are for example to be used in quadruple format in the same reaction mixture, as already described in detail in connection with other aspects of the invention.

[0688] Thus, the method according to the invention allows the detection of an amplification product indicating the specific presence of at least one species of Mycobacterium among at least 217 different species, subspecies or variants of Mycobacterium in the pharmaceutical product, and the absence of an amplification product indicating the absence of any species of Mycobacterium in the pharmaceutical product.

[0689] Therefore, this approach is suitable as an alternative safety release test and can be used as is after product validation according to regulatory requirements.

[0690] With respect to the three primer pairs and associated probes that hybridize to the rrs gene, various alternative systems are described with respect to other aspects of the invention and are fully applicable to this method.

[0691] The present invention also relates to different methods, in particular a method for releasing a pharmaceutical product which has passed the safety release test as disclosed above based on the absence of detection of any amplification product using the three primer pairs and the associated probes of the present invention.

[0692] The present invention also relates to a method for producing a biopharmaceutical product comprising the step of testing for mycobacterial contamination by carrying out the method according to the present invention for detecting the sequence of the rrs gene of any mycobacterium.

[0693] The present invention also relates to a method for producing a biopharmaceutical product free of mycobacterial contamination, the method comprising:

[0694] - Provide biological drug products, and

[0695] - subjecting said product to the method according to the invention for detecting the sequence of the rrs gene of any mycobacterium.

[0696] According to this method it is concluded that if no amplification product is detected by the method of the invention, the product is free of mycobacterial contamination.

[0697] The biopharmaceutical product may be a biological product or a pharmaceutical product; a suitable product is a vaccine.

[0698] Also for this aspect, all specific features which have been disclosed in connection with the previous aspects of the invention also apply.

[0699] Example:

[0700] Mycobacterium detection is a safety release test that may be required for biological drug products expressed in or based on eukaryotic cells. The current method described in the pharmacopoeia is based on microbial culture (see European Pharmacopoeia Chapter 2.6.2 and WHO Technical Report Series-TRS 978 Section B.11.3.3). It requires the sample to be tested to be inoculated in triplicate into two different suitable solid culture media and one suitable liquid culture medium. All cultures are incubated for 56 days.

[0701] The major problems and limitations of the above mentioned pharmacopeia culture-based assays are inter alia the availability and potential shortage of specific culture media, the very long test turnaround time of 56 days, and the lack of detection of important species of human origin, namely Mycobacterium leprae, which is an obligate intracellular parasite, as well as the lack of detection of other intracellular mycobacteria or fastidious species with specific growth requirements, and therefore the lack of exhaustiveness of this assay.

[0702] Therefore, the inventors have developed an alternative method, which is:

[0703] - specific and exhaustive, i.e., able to detect low levels of all mycobacterial species but not other species besides mycobacteria;

[0704] - Rapid, meaning results are available in a few days or less; and

[0705] -Sensitive enough to replace pharmacopoeial methods.

[0706] Furthermore, this approach is compatible with Good Manufacturing Practice.

[0707] Table 4 lists the different mycobacteria known to date and considered by the inventors.

[0708] Example 1: Materials and Methods

[0709] Strains:

[0710] Mycobacterium strains that have been used to validate the method include both slow growing strains and fast growing strains and are detailed in Table 1. The rationale for the selection of these strains is explained in Example 5.

[0711] When the reproductive cycle is 7 days or less, the growth rate is defined as fast (also defined as rapid). For mycobacteria with a reproductive cycle longer than 7 days, the growth rate is defined as slow.

[0712] Table 1 : List of strains, their references in the cell bank, their possible alternative names and their growth rates.

[0713]

[0714]

[0715] *Alternative names or heteronyms consider two nomenclatures for the genus Mycobacterium, namely according to Gupta et al. and according to Tortoli et al.

[0716] Generation and characterization of mycobacterial libraries.

[0717] The mycobacteria of the library have been characterized and calibrated by flow cytometry and digital PCR (dPCR).

[0718] DNA extraction and purification

[0719] For DNA purification, the QIAmp DNA Micro Kit (preliminary steps for primer design and LOQ determination) and the QIAamp UCP DNA Micro Kit (Qiagen) were used according to the manufacturer's recommendations.

[0720] Alternative commercially available kits have also been tested, such as MTB Isolation Kit (ElisabethPharmacon).

[0721] Amplification:

[0722] PCR amplification

[0723] Amplification is performed by a ready-to-use commercially available Master Mix for probe detection containing DNA Taq polymerase and oligonucleotides appropriate for the PCR technique used (eg, qPCR).

[0724] Extraction / amplification controls:

[0725] Exogenous internal controls for extraction and amplification will be used. The following 2 internal controls were tested:

[0726] -DiaControlDNA TM : Diagenode, reference DICD-CY-L100 with Cy5 detection.

[0727] This kit contains primers and probes, as well as seal herpes virus at a concentration of 1000 TCID50 / mL, which is unrelated to the mycobacterial gene and the product being evaluated.

[0728] - The second internal control is a plasmid containing the gene encoding GFP, which is unrelated to mycobacterial genes and the product being evaluated.

[0729] Appropriate primers and corresponding probes have been designed for detection of this control.

[0730] Primers and probes

[0731] The primers and probes used to amplify the rrs gene (16S rRNA) and detect the amplification products in the rrs gene are detailed in Table 2.

[0732] Table 2: Primers and probes specific for the Mycobacterium rrs gene. The fluorophore attached to probes S1-0, S3-0 and S4-0 at the 5' end is FAM; the quencher (at the 3' end) is MGB (minor groove binding).

[0733]

[0734]

[0735] The probe used to detect the internal control was linked to the fluorophore Cy5 at the 5' end, and the quencher at the 3' end was BHQ1.

[0736] Example 2: Selection of targets, primers and amplification methods.

[0737] In order to develop a faster, more exhaustive and easier to perform alternative to the pharmacopeia methods for the detection of mycobacteria, the inventors have tested different methods based on molecular biology rather than culture, and more specifically on sequence amplification.

[0738] Therefore, the inventors first designed potentially appropriate primers in silico, tested and compared different amplification methods, and constructed a calibrated mycobacterium library for validating the primers, specificity and exhaustiveness of the detection method, and for evaluating sensitivity.

[0739] 2.1. Selection of target to be amplified.

[0740] Genome-wide approach

[0741] In order to define an alternative to the pharmacopeia method, one approach to defining an appropriate target is to target a single gene or a single sequence that is strictly specific to a mycobacterial species. For this purpose, the full genomes of all species would be sequenced. Therefore, this approach requires that the full sequences of all mycobacterial species are available and of sufficient quality. However, this is not possible for all species, which compromises the exhaustiveness of the method. Therefore, the inventors overlooked this approach.

[0742] Gene-specific or region-specific approaches

[0743] Different genes or regions have been reported in the art as primary targets for the detection of mycobacteria (Bhatnagar et al. 2017). However, after studying these genes or regions, the inventors concluded that in most cases, these genes are only present in M. tuberculosis or only in non-tuberculous mycobacteria (NTM). Furthermore, the sequences of these genes are not available or reported for all species of the genus, which is incompatible with the required exhaustiveness.

[0744] The intergenic sequence between the rrs gene and the rrl gene encoding the 23S RNA (ITS1 region) has also been studied and tentatively retained. However, the corresponding sequence is not available for all mycobacteria, which jeopardizes the exhaustiveness of the detection; in addition, the ITS1 target does not seem to be specific enough for the required specificity.

[0745] The rrs gene is a gene encoding 16S rRNA and contains approximately 1400 base pairs. This is a primary target for detecting specific microorganisms because this gene contains conserved regions shared by several bacterial species and variable regions that depend on the species. In addition, the rrs genes of different species of mycobacteria appear to be well documented and are therefore retained by the inventors.

[0746] A file containing the sequence of the rrs gene in FASTA format was created from the Ezbiocloud database, which contains only sequences that have been checked for quality. This file contains 195 sequences corresponding to all the different species and subspecies known as mycobacteria.

[0747] In order to determine appropriate primers, these 195 sequences (which were subsequently completed to cover the 217 sequences known so far) have been aligned using the Clustal omega program, which is suitable for the alignment of multiple sequences.

[0748] 2.2. Design of primers and probes:

[0749] Single Primer Pair Method:

[0750] All available mycobacterial rrs gene sequences have been aligned. Once the sequences have been aligned, they are used in Primer express software (Thermo Fisher Scientific) to design primer pairs, and the associated MGB probes (minor groove binders). The software suggests different potential pairs, and the different sequences are then compared using PrimerBlast (NCBI) and de Silva test Prime (German Bioinformatics Infrastructure Network).

[0751] This step is necessary not only to check for mycobacterial sequences recognized by the primer pair or primers, but also to ensure specificity (ie, other bacterial species are not amplified and detected).

[0752] No primer mismatches were allowed on the database.

[0753] The results obtained by the selected primers were disappointing, as other species besides mycobacteria were amplified, insofar as the targeted regions for 195 species or subspecies were conserved regions among bacteria.

[0754] Therefore, it is not possible to design a single primer pair to amplify all sequences of only mycobacteria.

[0755] Multiple methods:

[0756] Since it is not possible to design a single primer pair to amplify only the rrs sequence from mycobacteria, but to amplify all rrs sequences, then the inventors decided to design primers for different mycobacterial groups based on their phylogenetic evolution and then look for appropriate primer pairs. The rationale for this approach is to identify a target region in the rrs gene that is more variable but specific to mycobacteria.

[0757] In addition, the inventors decided to design different groups to take advantage of previously The phylogenetic tree of the defined Mycobacterium genus is refined, as phylogenetically closer species are more likely to present common conserved regions that are unique to their group (Gupta et al., 2018).

[0758] In a first step, two primer pairs covering 175 different species were designed. The first pair (F1-1 and R1-1) allowed the detection of 151 species of mycobacteria. The second pair allowed the detection of 24 additional species, but about a hundred species were amplified by both pairs.

[0759] The remaining 20 sequences in FASTA format were realigned with another alignment software (i.e., Seaview). Primer Express (version 3) software generated new primer suggestions, which were then compared to different databases. Two additional primer pairs (F3-1 and R3-1 and F4-1 and R4-1) were thus obtained, which covered 17 additional species and were specific to Mycobacterium.

[0760] This generated four different primer pairs that target the same rrs gene but different regions.

[0761] With regard to the updating of the taxonomy, and the revision of the software defining primers and probes, the inventors determined that a second primer pair is not necessary to cover all mycobacteria, since systems 1, 3 and 4 cover all species mentioned so far.

[0762] The list of aligned mycobacterial species, including accession numbers and primer pairs that caused amplification, is detailed in Table 4. This table is based on the List of Prokaryotic names with Standing in Nomenclature (LPSN) and the following publications: Parte et al., 2018, Parte et al. 2020, Parte et al. 2014 and Euzéby 1997.

[0763] Table 4:

[0764]

[0765]

[0766]

[0767]

[0768]

[0769]

[0770]

[0771]

[0772]

[0773]

[0774]

[0775] **Not 100% tested in silico study, but the test has been validated by in vitro testing.

[0776] *: Mycobacterium elephantiasis: Close to the slow-growing mycobacteria (Mycobacterium parahaemolyticus and Mycobacterium cooki), but a fast-growing mycobacterium.

[0777] As can be seen in Table 4, for 5 species, namely M. geneva, M. maculatus, M. hessianus, M. thermosistible and M. heraklion, there is a mismatch between one of the primers and the rrs gene sequence of these species. Considering the position of these mismatches on the primers, and the fact that the mismatches involve primers and not probes, it can be inferred that this mismatch should not hinder amplification. This has been confirmed by the inventors (see Example 3).

[0778] Conclusion: The three primer pairs (F1-1 and R1-1, F3-1 and R3-1, and F4-1 and R4-1) allow the detection of the rrs gene of mycobacteria and cover all Mycobacterium species.

[0779] Confirmation of probe and specificity:

[0780] Using the same software, probes specific for the sequences amplified by the three primer pairs (F1-1 and R1-1, F3-1 and R3-1, and F4-1 and R4-1), namely S1-0, S3-0 and S4-0, respectively, have been designed. A perfect match between these probes and the amplified sequences is required.

[0781] In addition, the inventors have performed analyses using Primer-BLAST software developed at NCBI to help users prepare primers specific for intended PCR targets. This program uses BLAST and a global alignment algorithm to screen primers against a user-selected database to avoid primer pairs (all combinations, including forward-reverse primer pairs, forward-forward, and reverse-reverse pairs) that may result in nonspecific amplification. In the present case, the selected database is the RefSeq Representative Genome Database (organisms limited to bacteria).

[0782] The parameters of Primer BLAST were set as follows:

[0783]

[0784]

[0785] The number of Blast hits analyzed was 36477 for F1-1 and R1-1, 8072 for F3-1 and R3-1, and 8971 for F4-1 and R4-1.

[0786] The results are as follows:

[0787] For F1-1 and R1-1:

[0788] In the case where 2 mismatches were approved, the specificity was 98.72%.

[0789] Two of the 156 amplified sequences were not actually from mycobacteria. These two sequences were from:

[0790] - Lujinxingia litoralis strain B210 B210. However, the amplified fragment contains more than 1000 base pairs and is therefore incompatible with qPCR. In any case, this amplified fragment does not hybridize with probe S1-0.

[0791] - Virgibacillus indicus strain P2-C2. However, no amplification was detected with probe S1-0.

[0792] Therefore, the specificity with the selected probe S1-0 was 100%.

[0793] For F3-1 and R3-1 :

[0794] In case 2 mismatches were approved, the specificity was 100%.

[0795] Thirteen sequences were amplified, all from mycobacteria.

[0796] For F4-1 and R4-1 :

[0797] In case of approval of 2 mismatches, the specificity was 95.65%.

[0798] Eight of the 184 amplified sequences were not actually from mycobacteria but did not hybridize to probe S4-0.

[0799] in conclusion : The three primer pairs F1-1 and R1-1, F3-1 and R3-1, and F4-1 and R4-1 with the corresponding probes S1-0, S3-0 and S4-0 allow specific detection of all Mycobacterium species, while other bacteria are not tested.

[0800] 2.3. Refinement of the calibrated mycobacterial library

[0801] The generation of mycobacterial cell banks was performed during the exponential growth phase. The characterization of the viable mycobacterial concentration was performed by flow cytometry methods, and the genome copy number (GC) (live and dead bacteria) was determined in single copy reference genes by classical methods known to those skilled in the art, such as qPCR, dPCR, fluorimetry or UV detection.

[0802] The ratio between GC / mL and viable mycobacteria / mL was calculated and had to be as close to 1 (mostly viable microorganisms) as possible in order not to bias the genome amplification-based methods over the culture-based methods.

[0803] This calibration method provides a suitable mycobacterial cell library for use in PCR.

[0804] 2.4. Comparison of sensitivity obtained using different amplification methods.

[0805] Quantitative PCR (qPCR), also known as real-time PCR, and digital PCR (dPCR) have been evaluated in parallel.

[0806] For primer pairs F1-1 and R1-1 and F4-1 and R4-1 (and F2-R2, but this primer pair was not retained in the end), these primer pairs amplify sequences present in the genome of Mycobacterium bovis (M. bovis) (now classified as Mycobacterium tuberculosis BCG variant with respect to the latest developments in nomenclature). Therefore, this mycobacterium was used to determine the detection limit for these primer pairs according to the amplification method (i.e., qPCR or dPCR) based on the concentration evaluated as detailed in Section 2.3. Mycobacterial DNA was extracted with a suitable commercial kit, which was used according to the manufacturer's recommendations.

[0807] For the primer pair F3-1 and R3-1, the corresponding DNA of Mycobacterium irishii was used.

[0808] Amplification by dPCR

[0809] The inventors first tested this technique using primers targeting the ITS1 region.

[0810] The inventors then tested this technique with primer pairs targeting the rrs gene on M. bovis DNA (F1-1 and R1-1, F2 and R2, and F4-1 and R4-1) with the aim of evaluating the detection limit of this technique.

[0811] The samples were diluted until the signal disappeared, ie no positive droplets were detected. The detection limit was equivalent for the three primer pairs tested (including the F2-R2 pair, but not retained), regardless of the detection system, i.e. detection by probe or by Evagreen.

[0812] According to initial tests performed by the inventors (on libraries roughly calibrated by optical density), the detection limit is approximately up to 10 -4 dilution (for Mycobacterium tuberculosis BCG variants).

[0813] By optimizing the DNA extraction steps, PCR conditions including the number of cycles, it is expected that the sensitivity will be improved.

[0814] Amplification by qPCR

[0815] To evaluate the detection limit of this technique, an initial reference range was prepared, allowing estimation of the amount of DNA present from the detected amplification.

[0816] For this purpose, for each selected target, a corresponding synthetic reference nucleotide sequence is synthesized, introduced into a plasmid and quantified.

[0817] Using primer pairs F1-1 and R1-1, F2-R2, and F4-1 and R4-1, the respective associated probes S1-0, S2, and S4-0, and synthetic sequences (whose amounts in ng / mL were known), the inventors were then able to set reference ranges for detecting targeted sequences with the probes by qPCR.

[0818] According to initial tests performed by the inventors (on libraries roughly calibrated by optical density), the detection limit is approximately up to 10 -5 dilution (for Mycobacterium tuberculosis BCG variants).

[0819] In view of the sensitivity and rapidity of qPCR, and the fact that it is cheaper than dPCR, the inventors chose qPCR for the subsequent steps. In addition, this technology meets the requirements of good manufacturing practice (GMP).

[0820] Example 3: Exhaustive verification.

[0821] For five species (i.e., M. geneva, M. maculatus, M. hessianus, M. thermotolerans, and M. heraklion), there was a mismatch between one of the primers and the rrs gene sequence of these species. Considering the location of these mismatches on the primers and the fact that the mismatches involved the primers and not the probes, it can be inferred that this mismatch should not hinder amplification.

[0822] The inventors have confirmed this by testing three primer sets using synthetic rrs genes corresponding to each of the five species.

[0823] The results obtained by the inventors confirmed that F1-1 and R1-1 and / or F4-1 and R4-1 were able to amplify the rrs genes of these five species. These results are reported in Table 4, "No*" means no amplification based on computer simulation studies, but amplification in vitro.

[0824] Therefore, the combination of the three primer pairs disclosed in Example 2 allows the amplification of the rrs gene of each and all mycobacteria.

[0825] Example 4: Validation of multiplex amplification.

[0826] In the first step, the inventors performed a duplex amplification. Samples of different concentrations of M. tuberculosis BCG variants have been prepared with or without internal controls (IC), i.e., spiked with the internal control of the Diagenode kit (spiked at 10 TCID50) or spiked with the internal control GFP plasmid (spiked at 10 6 The internal control worked well for both tests (data not shown), but for further steps the inventors used GFP IC.

[0827] Different samples (containing different concentrations of DNA extracted from M. tuberculosis BCG variants and an internal control) have been analyzed by qPCR under the following conditions:

[0828] - Singleplex: primer pair F1-1 and R1-1 for amplification of the rrs gene only, or primer pair for amplification of the internal control only and an appropriate probe, and

[0829] - Dual: Simultaneous with primer pair F1-1 and R1-1 and primer pair IC and appropriate probes.

[0830] The results obtained showed that both the targeted rrs gene and the internal control could be detected simultaneously. Figure 1A and Figure 1B As shown, there was no difference in the detection of the targeted rrs gene or the internal control between the singleplex and duplex setups.

[0831] As can also be seen in these figures, there is no fluorescence interference between the probe for the rrs gene (fluorophore FAM) and the probe for the internal control (fluorophore Cy5) because the wavelengths are sufficiently different, i.e.:

[0832] FAM: excitation at 490nm / emission at 520nm

[0833] Cy5: excitation at 650 nm / emission at 670 nm.

[0834] To confirm the above results, the experiment was repeated using 3 different primer pairs and relevant probes.

[0835] Already 10 5 , 10 4 and 10 3 Mycobacterium tuberculosis BCG variants were extracted and have been tested at 10 5 The GFP plasmid was spiked in at a concentration of 5 copies / 5 μL. The same operation was performed with DNA from Mycobacterium irishigii at concentrations of 5.3 pg / μL and 5.3 fg / μL.

[0836] Using qPCR, the three systems disclosed in Example 2 (primers and corresponding probes) as well as primers and probes for the GFP plasmid were tested first in singleplex reactions and then in duplex reactions.

[0837] The inventors then concluded that singleplex and duplex amplification did not alter the results obtained by qPCR.

[0838] Multiplex detection

[0839] The inventors first tested duplex qPCR amplification with targeted M. tuberculosis BCG variants and both the first system (F1-1, R1-1 and S1-0) and the fourth system (F4-1, R4-1 and S4-0).

[0840] The results show that dual qPCR is possible and allows for better detection of mycobacteria. In fact, these detection systems (i.e., the first system and the fourth system) amplify different regions of the rrs gene, so that there is no competition between the primers for the targeted DNA. The other components of the master mix (such as dNTPs, polymerase, etc.) are in excess, also ensuring that there is no competition between the primers for other resources. Insofar as the probes of both systems are detected by the same fluorophore, the signal is even amplified because the amplified sequence is increased by two times. This signal amplification is expected for all species that can be amplified by at least two of the three systems disclosed in Example 2.

[0841] Then, the inventors added an internal control (i.e., a GFP internal control), as well as relevant primers and probes, and performed triple qPCR. The results obtained showed that the triple reaction had no negative impact on the detection of the internal control. Similarly, the detection of the targeted rrs gene was homogenous.

[0842] Therefore, the inventors tested quadruple qPCR. In this regard, 4 different reactions have been performed:

[0843] - 3 duplicate reactions, corresponding to one of the 3 systems (system 1, system 3 or system 4) and an internal control (GFP plasmid) and the relevant primers and probes;

[0844] - 1 quadruple reaction using 3 systems and an internal control.

[0845] A side-by-side comparison of the results obtained for each system with the internal control alone or with the internal control in combination with the two additional systems allowed the conclusion that the quadruplex amplification gave satisfactory results with sufficiently high sensitivity and specificity. Figure 2 As can be seen, for each system (the first system: Figure 2 A; System 3: Figure 2 B; and System 4: Figure 2 C), With controls only, detection of targeted sequences is earlier or amplified in quadruplex relative to duplex detection.

[0846] Example 5: Validation of multiplex amplification of representative species.

[0847] The inventors then experimentally verified the detection method disclosed in Example 2 on mycobacteria under the quadruple conditions detailed in Example 4.

[0848] The 12 species / strains selected in the development and validation of the detection method are listed in Table 1 of Example 1. They represent a sample of the different genera contained in the mycobacteria (according to the previous classification, because the single mycobacterium genus has now been reconstructed according to the latest classification, but there is no change in the bacteria considered as mycobacteria); in fact, 4 of the 5 different mycobacterial genera are represented, namely Mycobacterium, Mycolic acid bacillus, Mycolic acid bacillus and Mycobacterium. The Mycobacterium microbacterium genus is not represented because it only contains 3 uncommon mycobacteria with very low occurrence rates.

[0849] Due to insufficient amounts of M. xenopus and M. chelonae available for this experiment, the inventors used synthetic rrs genes encoding 16S rRNA from these species. Regarding M. irish, for safety reasons the inventors worked with DNA that had been extracted from this mycobacterium.

[0850] All strains (including those represented only by DNA) had been extracted using one of the kits mentioned in Example 1; internal controls (GFP plasmid, 10 5 copies / 5 μL).

[0851] Then, the samples were analyzed by qPCR in quadruplex format using a commercial kit.

[0852] A standard range was obtained to quantify the extracted samples for defining the test detection limit for each test strain. This standard range was calibrated in pg / μL DNA and obtained with 6 points and 3 replicates. The error tolerance had to be lower than 0.1 and the linear regression coefficient had to be as close to 1 as possible.

[0853] Extracts from each strain were first analyzed by qPCR without dilution and then diluted to up to 10 -3 , to estimate the detection limit for each strain.

[0854] Figure 3 depicts the results ( Figure 3A : Slow-growing mycobacteria; Figure 3B : Rapidly growing mycobacteria).

[0855] In order for a given dilution to be considered "quantifiable" in quadruple conditions, both replicates needed to be similar (difference less than 0.8 Cp) and the result regarding Cp to be consistent with the previous dilution, ie, differ by 3.3 Cp from the previous dilution.

[0856] Cp means "crossing point", which is also called Cq, and is the number of amplification cycles beyond which amplification is considered significant, ie, above a threshold level. The threshold level is shown in FIG. Figure 2 and illustrated by lines in FIG. 3 .

[0857] The minimum amount of DNA amplified by the quadruplex detection system for each strain is summarized in Table 5. This is not the detection limit of the method, but rather a demonstration that the method is suitable for detecting very small amounts of DNA for each species.

[0858] Table 5:

[0859]

[0860]

[0861] In summary, the inventors have shown that the detection test detailed in Example 2 can detect targeted mycobacteria as well as an internal control in quadruple pools using standard extraction conditions.

[0862] The sensitivity for all strains was comprised between 0.03 and 0.005 fg / μL, except for M. irishigianum (0.26 fg / μL).

[0863] Conclusion of Examples 2-5:

[0864] The inventors have demonstrated that the qPCR-based technique and the primers, probes and conditions disclosed in these examples provide a suitable test for detecting the presence of mycobacteria in the absence of culture. This technique provides results faster than the culture-based pharmacopeia method, as it provides results in 2 days or even significantly less. Thus, the time to obtain results can be shortened by up to 96% relative to the pharmacopeia method.

[0865] qPCR is also a technique that is compatible with a GMP environment.

[0866] Furthermore, the above results show that the detection of mycobacteria is exhaustive, as demonstrated by computer simulations and proof of concept with representative numbers of mycobacteria.

[0867] Furthermore, the test detailed in the examples is particularly efficient because it allows simultaneous detection with three systems and with internal controls.

[0868] The specificity of the detection has also been demonstrated by comparison with other bacterial sequences; this specificity is provided by the probes.

[0869] The sensitivity of the method can be further improved by optimizing the extraction steps and the conditions of qPCR.

[0870] Finally, although proof of concept has been established with qPCR, the inventors have also begun testing with other techniques such as dPCR that appear to be suitable for detection, especially because exhaustiveness and specificity depend on the design of primers and probes rather than the amplification method itself.

[0871] Example 6: Mycobacterium detection test

[0872] In view of the results obtained in Examples 1-5, the inventors have therefore defined a suitable method for detecting mycobacteria in a sample by qPCR, which method is exhaustive and specific.

[0873] This method can detect virtually any mycobacterium, that is, from any of the following 5 genera:

[0874] -Mycolic acid bacilli

[0875] - Mycobacterium

[0876] - Mycobacterium

[0877] - Mycolic acid bacillus

[0878] - Mycobacterium

[0879] In total, 200 species and 217 species, subspecies or variants are represented (see Table 4). The new classification has no impact on the number of mycobacteria.

[0880] The method relies on 3 different primer pairs and associated probes designed as detailed in Example 2 to amplify a region of the sequence of the rrs gene of any mycobacterium. The 3 different primer pairs or systems target different regions of the rrs gene. The 3 associated probes are coupled to a FAM fluorophore.

[0881] The fourth primer pair and associated probe are used to detect an internal exogenous control. The control probe is coupled to Cy5 or to another fluorophore other than FAM.

[0882] The internal exogenous control can be any DNA sequence that has been extracted or is present in a microorganism that is not related to the mycobacteria to be detected. In particular, the control is added to the sample during the extraction step. It allows to control this extraction step and, in the case that the mycobacteria do not amplify, it ensures that this is not related to a defective extraction step.

[0883] All primers (ie, four primer pairs) and all probes (ie, four probes) are mixed together in a single reaction mixture for PCR. Thus, a single PCR reaction is sufficient to detect all mycobacteria that may be present in a sample, corresponding to a quadruple detection.

[0884] Primers F1-1, R1-1, F3-1, R3-1, F4-1 and R4-1 are the primers disclosed in Table 2 of Example 1.

[0885] Primers and probes suitable for an internal control will also be added; the fluorophore coupled to the probe detecting the internal control must be different from the FAM fluorophore to distinguish amplification from systems 1, 3, and 4 indicating the presence of mycobacteria from amplification from the control system indicating the presence of the control.

[0886] For qPCR, prepare the reaction mixture according to the number of samples to be analyzed and the necessary volume per well (between 20 and 50 μL):

[0887] - Commercial master mix qPCR with probes: Taq polymerase, dNTPs, Mg2+, buffer (non-exhaustive list),

[0888] - Primers at concentrations between 100 nM and 400 nM

[0889] - probes with a final concentration between 50 nM and 250 nM

[0890] - Primers and probes suitable for internal control of extraction

[0891] - Nuclease-free water qsp

[0892] The composition of the master mix and the concentrations of primers and probes can be adjusted to increase the sensitivity or specificity of the assay.

[0893] The reaction mixture is then placed in the wells of a 96-well plate and the samples are then added. The plate is coated, centrifuged, and inserted into a thermal cycler.

[0894] The number of cycles is adjusted according to the enzymes present in the mixture. The hybridization temperature is defined according to the fusion temperature of the primers and probe.

[0895] Positive and negative controls for extraction and for qPCR are advantageously added.

[0896] Example 7: Primer and probe design variations

[0897] As for the foregoing examples demonstrating that defined primer sets and probes can specifically and exhaustively detect the rrs genes of all mycobacteria, the inventors have demonstrated that variations of primers and probes can be designed without losing the specificity and exhaustiveness of the original primers and probes.

[0898] Therefore, the inventors have studied different variations by computer simulation, and more specifically studied the interpolation or suppression of 1 to 4 bases at each end. The research is intended to define the impact of these modifications on the specificity and thoroughness of initial primers and probes. In this respect, primer design software (such as Primer Expresss) and international databases (such as PrimerBlast) have been used. In addition, the inventors have tested the composition of primer variants and the combination of probes.

[0899] Materials and Methods

[0900] As an initial step, 217 rrs gene sequences of mycobacterial origin, corresponding to a total of 200 different species and 217 species, subspecies or variants, have been aligned using the software Geneious (10.2.6) and the program Clustal W. Based on this alignment, the three primer pairs identified in Example 2, namely F1-1 and R1-1, F3-1 and R3-1, and F4-1 and R4-1, were located.

[0901] Based on this alignment view, modifications that may be introduced into the primers without compromising exhaustiveness are defined. With regard to the probes, the acceptable modifications are far less extensive, in that the probes must be based on the sequence amplified by the primers, and are therefore limited to the sequences that lie between the primer sequences (separated by 1 or 2 bases). This point also emphasizes that the sequence of the primer pair is closely related to the sequence of the associated probe.

[0902] Design of primer variations:

[0903] Primer changes were initially designed using the program Primer3 based on Primer Blast data. They were named F1-2, F1-3 (for primer F1), etc. ...; F1-1, R1-1, F3-1, R3-1, F4-1 and R4-1 correspond to the initial design. For each change, the GC content (percentage) and Tm (melting temperature) were calculated. These changes were then analyzed for consistency using the software Primer Express (i.e., the same software used with the initial primers), which was set to quantify with the probe MGB (minor groove binder).

[0904] For each primer variation tested, the following parameters / criteria set by the program should be met in order for the variation to be retained:

[0905] - Primer Tm (melting temperature) must be between 58°C and 60°C;

[0906] - The probe Tm (melting temperature) must be between 68°C and 71°C;

[0907] The GC content must be between 40% and 70%, in particular about 50%.

[0908] Furthermore, the difference between the Tm of a pair of primers must not exceed 2°C, and the difference between the Tm of the probe and primers must be approximately 10°C.

[0909] In a first step, based on this criterion, different primer pairs and the associated original probes (ie, S1-0, S3-0 and S4-0 without changes) were tested.

[0910] Then in the second step, the probe variations are tested in combination with the primer pairs (variations) retained and selected in the first step.

[0911] In the end, two different types of results are retained:

[0912] - Primer and probe combinations that fully meet all criteria, as also the initial design of primers and probes. As demonstrated by the initial design, these combinations should be suitable for selective and exhaustive amplification.

[0913] - Combinations where one requirement is not fully met (e.g. primer Tm is comprised between 57°C and 58°C or between 60°C and 61°C, i.e. differs by 1°C or less from the set standard), but fully meet the other criteria. These combinations are also expected to be fully suitable for the intended purpose.

[0914] Specificity analysis:

[0915] Once the different combinations are retained based on the criteria and selections mentioned above, the specificity of the different primer pairs and associated probes are tested to ensure that there is no loss of specificity.

[0916] result:

[0917] 1. Primer combinations

[0918] The various changes to the primer sequences are detailed in Table 6 below, specifically illustrating modifications at the 5' end and the 3' end relative to the initial design.

[0919] Table 6:

[0920]

[0921]

[0922] For each system that amplifies a different region of the rrs gene (ie, System 1, System 3, and System 4), each variation of the forward primer was tested with each variation of the reverse primer, including the original design, using PrimerExpress software.

[0923] Thus F1-1 was tested independently along with R1-1 (initial pair, no changes), R1-2, R1-3, R1-4, R1-5 and R1-6. The same applies to F1-2, F1-3 and F1-4.

[0924] The same combination strategy applies to Systems 3 and 4.

[0925] It is emphasized in this regard that a given change in the forward primer may actually be suitable in combination with a specific change in the reverse primer and unsuitable in combination with another change in the reverse primer. This is why changes in the forward and reverse primers are tested in pairs.

[0926] The following tables (Tables 7, 8, and 9) report the following combinations for each system: all criteria were met (++); only one parameter did not fully meet one of the criteria, but the difference was still acceptable (+), usually a Tm difference of 1°C from the targeted Tm; and one or more of the criteria were not met (-), which represents a less favorable primer sequence.

[0927] Table 7 : System 1

[0928] 1 F1-1 F1-2 F1-3 F1-4 R1-1 Combination 1(++) Combination 7(+) Combination 13 (-) Combination 19(-) R1-2 Combination 2 (-) Combination 8(-) Combination 14 (-) Combination 20(-) R1-3 Combination 3 (-) Combination 9(+) Combination 155(-) Combination 21(-) R1-4 Combination 4 (-) Combination 10(-) Combination 16 (-) Combination 22 (-) R1-5 Combination 5(+) Group 11(+) Combination 17 (-) Combination 23 (-) R1-6 Combination 6(++) Combination 12(+) Combination 18(+) Combination 24 (-)

[0929] Table 8 : System 3

[0930] 1 F3-1 F3-2 F3-3 F3-4 R3-1 Combination 1((++) Combination 5 (-) Combination 9(++) Combination 133(-) R3-2 Combination 2 (+) Combination 6 (-) Combination 10(+) Combination 14 (-) R3-3 Combination 3 (+) Combination 7(-) Combination 11(+) Combination 15(-) R3-4 Combination 4 (+) Combination 8(-) Combination 12(+) Combination 16 (-)

[0931] Table 9 : System 4

[0932] 1 F4-1 F4-2 F4-3 F4-4 F4-5 R4-1 Combination 1(++) Combination 7(-) Combination 133(+) Combination 19)(-) Combination 25(++) R4-2 Combination 2 (-) Combination 8(-) Combination 14 (-) Combination 20(-) Combination 26 (-) R4-3 Combination 3 (+) Combination 9(-) Combination 15(+) Combination 21(-) Combination 27(+) R4-4 Combination 4 (-) Combination 10(-) Combination 16 (-) Combination 22 (-) Combination 28(-) R4-5 Combination 5(+) Combination 11(-) Combination 177(-) Combination 23 (-) Combination 29 (-) R4-6 Combination 6 (-) Combination 122((-) Combination 18(-) Combination 24 (-) Combination 30(+)

[0933] 2. Combination of probes

[0934] The variations of probes S1-0, S3-0 and S4-0 that have been tested as well as the modifications at the 5' and 3' ends are reported in Table 10.

[0935] Table 10 :

[0936]

[0937] Different associations have been established between the primer combinations with results (++) or (+) detailed in Tables 7 to 9 and the relevant probes and variations of Table 10.

[0938] The following tables (Tables 11-13) report the following associations for each system: all criteria were met (++); one parameter did not fully meet one of the criteria, but the difference was still acceptable (+); and one or more of the criteria were not met (-), representing a less favorable association.

[0939] Table 11 : System 1:

[0940]

[0941] Table 12 : System 3:

[0942]

[0943] Table 13 : System 4:

[0944]

[0945] 3. Specificity

[0946] The inventors have checked whether combinations of primers that have been retained could amplify sequences other than mycobacterial sequences using the tool Primer BLAST in the NCBI database.

[0947] System 1

[0948] For combinations 6, 5, 7, 11 and 18 detailed above, the primer BLAST results showed the same specificity as combination 1 (corresponding to the original primers). Therefore, these changes did not compromise specificity.

[0949] System 3:

[0950] For combinations 9, 2, 3, 10, 11 and 12 detailed above, the primer BLAST results showed the same specificity as combination 1 (corresponding to the original primers). Therefore, these changes did not compromise specificity.

[0951] System 4:

[0952] For this system, it has been shown that specificity is provided by probe S4-0 for the primer pair disclosed in Example 2. In order to preserve this specificity provided by the probe, the inventors concluded that the 5' end of the probe must not be shortened, i.e. S4-2 and S4-3 were unacceptable; therefore only the change corresponding to S4-1 was retained.

[0953] For the combinations 13, 25, 3, 15, 27 and 30 detailed above, the primer BLAST results showed the same specificity as combination 1 (corresponding to the original primers). Therefore, these changes did not compromise specificity.

[0954] Combination 5 amplified 13 additional species of non-mycobacterial origin; however, specificity was preserved in combination with probe S4-0 (original design).

[0955] Thus, these results show that not only the 3 primer pairs and associated probes corresponding to the following have demonstrated their ability to specifically and exhaustively detect mycobacteria using probe detection by PCR-based amplification methods:

[0956] F1-1 and R1-1 with probe S1-0

[0957] F3-1 and R3-1 with probe S3-0

[0958] F4-1 and R4-1 with probe S4-0,

[0959] And slight changes in the primers and the probes also share the same capabilities.

[0960] Example 8: Further verification of specificity.

[0961] The inventors have verified the specificity of the methods disclosed in Examples 4 and 5 demonstrated in Example 2, especially with respect to other non-mycobacterial bacteria, and in the presence of a matrix.

[0962] 8.1. Testing on Other Species.

[0963] Four other species were selected to evaluate the specificity of qPCR under the conditions detailed in Examples 4 and 5, using primers and probes F1-1, R1-1, S1-0, F3-1, R3-1, S3-0, F4-1, R4-1 and S4-0. In this regard, the species selected by the inventors are those considered to be phylogenetically very close to the genus Mycobacterium (Actinobacteria), namely:

[0964] Nocardia asteroides

[0965] ·Cutibacterium acnes

[0966] Corynebacterium diphteriae

[0967] Dietzia papillomatosis

[0968] Each strain was characterized by a viable bacterial concentration of 100 CFU / mL.

[0969] Mycobacterium qPCR tests were performed on the mycobacterial strain M. tuberculosis BCG variant (positive control) as well as on different actinomycete strains at the same time and using the same experimental conditions.

[0970] The results obtained for 100 CFU / mL of Nocardia asteroides and 100 CFU / mL of Dietzia papillomaviruses are shown in Figure 4 A and Figure 4 In B. Comparable results were obtained with 100 CFU / mL of Propionibacterium acnes (C. acnes) and 100 CFU / mL of Corynebacterium diphtheriae (C. diphteriae).

[0971] These results show specific detection of mycobacterial strains, while lacking detection of the other four Actinomycetales strains, with cycle numbers between 37 and 40, depending on the strain. Thus, for the experimental conditions of this test, the cycle threshold is approximately 37 cycles.

[0972] These results demonstrate that qPCR is specific for the detection of mycobacterial strains using the primers and probes designed by the inventors.

[0973] Comparison with pharmacopoeia determination:

[0974] To compare the specificity of the qPCR method of the present invention with the culture-based pharmacopeia method, the pharmacopeia assay was performed with the same strains at the same concentrations. For all four Actinomycetales strains, positive results were obtained on spiked liquid culture medium.

[0975] Thus, Nocardia asteroides, Propionibacterium acnes, Corynebacterium diphtheriae, Dietzia papilloma were detected by the Mycobacterium test on culture medium (corresponding to the pharmacopeia assay), but not by the qPCR of the present invention ("qPCR Mycobacterium") which specifically detects Mycobacterium.

[0976] Thus, the method according to the invention allows a specific detection, which is more specific than classical methods involving cultivation.

[0977] 8.2. Testing on substrates.

[0978] The qPCR mycobacterium according to the present invention can be used for drug product testing.

[0979] The inventors have actually verified that this technique can be implemented with different matrices, demonstrating that there is neither non-specific cross-detection nor PCR inhibition by matrix components. Therefore, the qPCR mycobacterial technique can be implemented for drug product testing. Therefore, the qPCR mycobacterial technique can be implemented as a step in the production of biopharmaceutical products to test for mycobacterial contamination.

[0980] The matrices tested by the inventors are as follows:

[0981] -Supernatant of CHO cells producing recombinant cytomegalovirus protein antigen;

[0982] - Crude HAV (Hepatitis A virus) harvest produced on MRC5 cells;

[0983] - Yellow fever virus crude harvest produced on Vero cells;

[0984] - Crude rabies virus harvest produced on Vero cells.

[0985] Under the experimental conditions detailed in Examples 4 and 5, mycobacterial qPCR assays were performed using primers and probes F1-1, R1-1, S1-0, F3-1, R3-1, S3-0, F4-1, R4-1, and S4-0 on matrices spiked with different concentrations (ranging from 10 5 to 10 viable mycobacteria / mL) or two concentrations (10 5 (simulating high-level contamination) and 10 (simulating low-level contamination) viable mycobacteria / mL) of mycobacterium strain Mycobacterium tuberculosis BCG variant.

[0986] The results obtained on the matrix and on the PBS samples were similar; some of them were presented in Figure 5 A. Figure 5 B and Figure 5 C.

[0987] Conclusion: The qPCR mycobacterium according to the invention allows the detection of M. tuberculosis BCG variants on different matrices. This confirms that the matrices do not induce PCR inhibition and that there is no nonspecific amplification on unspiked matrices. Therefore, the qPCR of the invention is suitable for drug product testing at any step of its production, in particular on the final product, on any intermediate matrix, on virus seeds and on starting materials such as cell cultures or culture media.

[0988] Example 9: Demonstration of qPCR sensitivity.

[0989] 9.1. Mycobacterium samples tested:

[0990]

[0991] * = In-house strain

[0992] 9.2. Test substrates.

[0993] For Mycobacterium tuberculosis BCG variants, Mycobacterium avium, Mycobacterium irishii, Mycobacterium toadense, and Mycobacterium phlei: >10 6 The high concentration of Vero cell suspension at 10 cells / mL, serum and antibiotics are well known to be molecules that interfere with nucleic acid-based assays, which corresponds to the “worst case scenario” that may be encountered in drug product manufacturing.

[0994] For M. flavivirus, M. fortuitum, M. abscessus, and M. kansasii: Vero Yellow Fever Virus Crude Harvest Matrix.

[0995] 9.3. Methods.

[0996] The dilution range for each strain detailed in section 9.1 was performed in PBS up to 10 or 1 viable mycobacterium / mL (depending on the strain tested).According to Table 14, the samples with the matrix (see 9.2) were spiked with appropriate dilutions of the mycobacterial strains.

[0997] Table 14: Final dilution of each mycobacterial strain in matrix

[0998] Species Dilution 1 Dilution 2 Dilution 3 Mycobacterium tuberculosis BCG variants 100 10 1 Mycobacterium avium 100 10 1 Mycobacterium irish 100 10 1 Mycobacterium toadense 10 1 0,1 Mycobacterium phlei 10 1 0,1 Mycobacterium flavescens 10 1 NA Mycobacterium fortuitum 10 1 NA Mycobacterium kansasii 100 10 NA Mycobacterium abscessus 100 10 NA

[0999] The volume of the sample to be analyzed was 1,5 mL. Taking into account the extraction volume and the fact that the entire extraction product would be analyzed by qPCR, 6 determinations were performed for one sample.

[1000] If one out of six assays was positive (significant amplification), the sample was considered positive for the presence of the mycobacterial strain.

[1001] Results

[1002] 1 viable mycobacterium / mL of Mycobacterium tuberculosis BCG variant:

[1003] Four of the six assays showed positive and significant PCR amplification (i.e., above threshold, approximately 37-40 PCR cycles, as opposed to negative (unspiked) controls). Figure 6 A.

[1004] Therefore, the test was positive at this concentration and 1 viable mycobacterium / mL constituted the limit of detection.

[1005] 1 viable mycobacterium / mL of Mycobacterium avium:

[1006] Four of the six assays showed positive and significant PCR amplification (ie, above threshold, approximately 37-40 PCR cycles, as opposed to the negative (unspiked) controls).

[1007] The test was positive at this concentration and 1 viable mycobacterium / mL constituted the limit of detection.

[1008] 1 viable mycobacterium / mL of Mycobacterium irishii:

[1009] 6 of 6 assays showed positive and significant PCR amplification (i.e., above threshold, approximately 37-40 PCR cycles, as opposed to negative (unspiked) controls). Figure 6 B.

[1010] The test was positive at this concentration and 1 viable mycobacterium / mL constituted the limit of detection.

[1011] 0.1 viable mycobacteria / mL of Mycobacterium toadense:

[1012] Six of the six assays showed positive and significant PCR amplification (ie, above threshold, approximately 37-40 PCR cycles, as opposed to the negative (unspiked) controls).

[1013] The test was positive at this concentration and 0.1 viable mycobacteria / mL constituted the limit of detection.

[1014] 0.1 viable mycobacteria / mL of Mycobacterium phlei:

[1015] 6 of 6 assays showed positive and significant PCR amplification (i.e., above threshold, approximately 37-40 PCR cycles, as opposed to negative (unspiked) controls). Figure 6 C.

[1016] The test was positive at this concentration and 0.1 viable mycobacteria / mL constituted the limit of detection.

[1017] 10 viable mycobacteria / mL of Mycobacterium flavescens:

[1018] Four of the six assays had positive and significant PCR amplification (ie, above threshold, approximately 37-40 PCR cycles, as opposed to negative (unspiked) controls).

[1019] The test was positive at this concentration and 10 viable mycobacteria / mL constituted the limit of detection.

[1020] Mycobacterium fortuitum with 10 viable mycobacteria / mL:

[1021] Three of the six assays had positive and significant PCR amplification (ie, above threshold, approximately 37-40 PCR cycles, as opposed to negative (unspiked) controls).

[1022] The test was positive at this concentration and 10 viable mycobacteria / mL constituted the limit of detection.

[1023] Mycobacterium abscessus at 10 viable mycobacteria / mL:

[1024] Two of the six assays had positive and significant PCR amplification (ie, above threshold, approximately 37-40 PCR cycles, as opposed to the negative (unspiked) controls).

[1025] The test was positive at this concentration and 10 viable mycobacteria / mL constituted the limit of detection.

[1026] · 10 viable mycobacteria / mL of Mycobacterium kansasii:

[1027] Five of the six assays had positive and significant PCR amplification (ie, above threshold, approximately 37-40 PCR cycles, as opposed to negative (unspiked) controls).

[1028] The test was positive at this concentration and 10 viable mycobacteria / mL constituted the limit of detection.

[1029] Conclusion

[1030] The limit of detection in a complex matrix (crude harvest of Vero yellow fever virus) was 10 viable mycobacteria / mL for the following species: M. flavum, M. fortuitum, M. abscessus, and M. kansasii.

[1031] The limit of detection in a complex matrix (high concentration of Vero cell cultures) is 1 viable mycobacterium / mL for the following species: Mycobacterium tuberculosis BCG variants, Mycobacterium avium, and Mycobacterium irishig.

[1032] The detection limit in a complex matrix (high concentration of Vero cell cultures) was 0.1 viable mycobacteria / mL for the following species: Mycobacterium xenopi and Mycobacterium phlei.

[1033] This demonstrates the very high sensitivity of the method, allowing detection of representative mycobacterial strains at concentrations as low as 10 or 1 viable mycobacteria / mL, and even lower for some strains, even in complex matrices such as highly concentrated Vero cell cultures or crude viral harvest vaccines. Therefore, the qPCR mycobacterial technique can be implemented as a step in the production of biopharmaceutical products to test for mycobacterial contamination.

[1034] References

[1035] Bhatnagar,J.et al.(2017).Improved Detection and Accuracy ofMycobacterium Species Identification from Paraffin Embedded Tissues ofPatients by Using Multigene Targeted PCR and Sequencing.Open Forum InfectiousDiseases 4,S620–S621.

[1036] Euzéby, JP (1997). List of Bacterial Names with Standing in Nomenclature: a Folder Available on the Internet. International Journal of Systematic Bacteriology, 47, 590-592.

[1037] Gupta,RS,Lo,B.,and Son,J.(2018).Phylogenomics and ComparativeGenomic Studies Robustly Support Division of the Genus Mycobacteriuminto anEmended Genus Mycobacterium and Four Novel Genera.Frontiers in Microbiology9,67.

[1038] Haig,S.-J.,Kotlarz,N.,LiPuma,J.J.,and Raskin,L.(2018).A High-Throughput Approach for Identification of Nontuberculous Mycobacteria inDrinking Water Reveals Relationship between Water Age and Mycobacteriumavium.MBio9.9:e02354-17.

[1039] Meehan,C.J.,Barco,R.A.,Loh,Y.-H.E.,Cogneau,S.,and Rigouts,L.(2021).Reconstituting the genus Mycobacterium.International Journal of Systematicand Evolutionary Microbiology 71:004922.

[1040] Parte,A.C.(2014).LPSN—List of Prokaryotic names with Standing inNomenclature.Nucleic Acids Research,42,Issue D1,D613–D616

[1041] Parte,A.C.(2018).LPSN—List of Prokaryotic names with Standing inNomenclature(bacterio.net),20years on.International Journal of Systematic andEvolutionary Microbiology,68,1825-1829.

[1042] Parte,A.C.,et al.(2020).List of Prokaryotic names with Standing inNomenclature(LPSN)moves to the DSMZ.International Journal of Systematic andEvolutionary Microbiology,70,5607-5612.

[1043] Riojas,M.A.et al.(2018).Phylogenomic analysis of the species of theMycobacterium tuberculosis complex demonstrates that Mycobacterium africanum,Mycobacterium bovis,Mycobacterium caprae,Mycobacterium microti andMycobacterium pinnipedii are later heterotypic synonyms of Mycobacteriumtuberculosis.Int J Syst Evol Microbiol.68(1):324-332.

[1044] Tortoli E,Brown-Elliott BA,Chalmers JD,et al.(2019)Same meat,different gravv:ignore the new names of mycobacteria.Eur Respir J 2019;54.

Claims

1. A primer set for amplifying by polymerase chain reaction (PCR) the sequence of any Mycobacterium rrs gene present in a sample, wherein the set comprises at least three of the following primer pairs: Pair 1: Forward primer F1, which has the sequence: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) or a modification thereof, Reverse primer R1 having the sequence: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2) or a modification thereof; Pair 2: Forward primer F3, which has the sequence: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) or a modification thereof, Reverse primer R3, which has the sequence: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5) or a modification thereof; Pair 3: Forward primer F4, which has the sequence: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7) or a modification thereof, Reverse primer R4, which has the sequence: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8) or a modification thereof; wherein the modification is an addition and / or deletion of 1 to 4 nucleotides at the 3' and / or 5' termini, and / or a substitution of 1 or 2 nucleotides, and The three primer pairs described allow amplification of sequences of the rrs gene from any mycobacterial species.

2. The primer set according to claim 1, wherein the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 5) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-3: 5'-CACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 27); 6) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 7) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); and 8) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13).

3. The primer set according to any one of claims 1 to 2, wherein the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 6) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); 7) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17); as well as 8) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17).

4. The primer set according to any one of claims 1 to 3, wherein the third primer pair is selected from: 1) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 2) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 3) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 4) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 5) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-5: 5'-GCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 28); 6) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 7) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); as well as 8) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

5. A kit for amplifying the Mycobacterium rrs gene sequence in a sample by PCR, the kit comprising the primer set according to any one of claims 1 to 4.

6. The kit according to claim 5, which is used to detect the Mycobacterium rrs gene sequence amplified by PCR in a sample, and the kit further comprises the following related probes for detecting one or more amplification products: - Probe S1, which has the sequence 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3) or a modification thereof, for detecting the sequence amplified by the primers F1 and R1; - Probe S3, which has the sequence: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6) or a modification thereof, for detecting the sequence amplified by the primers F3 and R3; - a probe S4 having the sequence: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) or a modification thereof, for detecting the sequence amplified by the primers F4 and R4, The modification is the addition and / or deletion of 1 to 2 nucleotides at the 3' and / or 5' terminus.

7. The kit according to claim 6, wherein the probe is selected from: a) For the probe S1, selected from: Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), Probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23); Wherein when the probe S1 is S1-1, the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); and 5) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); When the probe S1 is S1-2, the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2); 5) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12); as well as 6) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); b) For the probe S3, selected from: Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), Probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and probe S3-2: 5'-CGGTTCCCTTGTGGC-3' (SEQ ID NO: 25); Wherein when the probe S3 is S3-1, the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); and 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); when the probe S3 is S3-2, the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17); and 6) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); c) for the probe S4, selected from: Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and probe S4-1: 5'-ACATGCTACAATGGCCGGT-3' (SEQ ID NO: 26); Wherein when the probe S4 is S4-1, the third primer pair is selected from: 1) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 2) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 3) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 4) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 5) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 6) forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); and 7) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

8. The kit according to any one of claims 5 to 7, which is used for amplification by quantitative polymerase chain reaction (qPCR) or by digital polymerase chain reaction (dPCR).

9. A method for amplifying and detecting the sequence of the rrs gene of any mycobacterium present in a sample, the method comprising the following steps performed simultaneously or sequentially: a) performing in vitro PCR on nucleic acids extracted from the sample using a set of at least three primer pairs according to any one of claims 1 to 4; b) Detecting the presence or absence of the amplified product.

10. The method according to claim 9, wherein the amplification step a) is performed by quantitative PCR or digital PCR.

11. The method according to any one of claims 9 to 10, wherein the detection step b) is performed using the following related probes: i) Probe S1 selected from: Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), Probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23); Wherein when the probe S1 is S1-1, the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); and 5) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); When the probe S1 is S1-2, the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2); 5) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12); as well as 6) forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); ii) probe S3, which is selected from: Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), Probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and probe S3-2: 5'-CGGTTCCCTTGTGGC-3' (SEQ ID NO: 25); Wherein when the probe S3 is S3-1, the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); and 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); when the probe S3 is S3-2, the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17); and 6) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); iii) probe S4 selected from: Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and probe S4-1: 5'-ACATGCTACAATGGCCGGT-3' (SEQ ID NO: 26); Wherein when the probe S4 is S4-1, the third primer pair is selected from: 1) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 2) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 3) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 4) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 5) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 6) forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); and 7) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

12. The method according to claim 11, wherein the amplification step a) is performed simultaneously in a single reaction mixture using the three primer pairs and the associated probes.

13. The method according to any one of claims 9 to 12, wherein the method comprises an initial step of extracting the nucleic acid from the sample before performing step a).

14. A method for detecting the presence of mycobacterial contamination in a pharmaceutical product without any culturing step, said method comprising the following steps performed simultaneously: a) amplifying in vitro nucleic acids extracted from a sample of the product by quantitative PCR (qPCR) or dPCR using at least three primer pairs according to any one of claims 1 to 4, wherein the primers hybridize to the rrs gene, b) Detecting the presence or absence of the amplified product by the following probes: i. Probe S1 selected from: Probe S1-0: 5'-CGGTGGGTACTAGGTGTG-3' (SEQ ID NO: 3), Probe S1-1: 5'-CGGTGGGTACTAGGTGT-3' (SEQ ID NO: 22) and Probe S1-2: 5'-CGGTGGGTACTAGGTG-3' (SEQ ID NO: 23); Wherein when the probe S1 is S1-1, the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); and 5) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); When the probe S1 is S1-2, the first primer pair is selected from: 1) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-1: 5'-CGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 2); 2) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); 3) Forward primer F1-1: 5'-CCTGGTAGTCCACGCCGTAA-3' (SEQ ID NO: 1) Reverse primer R1-5: 5'-ACGGATCCCAAGGAAGGAAAC-3' (SEQ ID NO: 12); 4) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-1: 5′-CGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 2); 5) Forward primer F1-2: 5'-CCTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 10) Reverse primer R1-5: 5′-ACGGATCCCAAGGAAGGAAAC-3′ (SEQ ID NO: 12); as well as 6) Forward primer F1-3: 5'-CTGGTAGTCCACGCCGTAAA-3' (SEQ ID NO: 11) Reverse primer R1-6: 5'-GGATCCCAAGGAAGGAAACC-3' (SEQ ID NO: 13); ii. Probe S3, which is selected from: Probe S3-0: 5'-TCGGTTCCCTTGTGGC-3' (SEQ ID NO: 6), Probe S3-1: 5'-ATCGGTTCCCTTGTGGC-3' (SEQ ID NO: 24) and probe S3-2: 5'-CGGTTCCCTTGTGGC-3' (SEQ ID NO: 25); Wherein when the probe S3 is S3-1, the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); and 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); when the probe S3 is S3-2, the second primer pair is selected from: 1) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 2) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-1: 5'-CATGCACCACCTGCACACA-3' (SEQ ID NO: 5); 3) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-2: 5'-CATGCACCACCTGCACACAG-3' (SEQ ID NO: 15); 4) Forward primer F3-1: 5'-CACAGGACGCCGGTAGAGAT-3' (SEQ ID NO: 4) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); 5) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-4: 5'-TGCACCACCTGCACACAG-3' (SEQ ID NO: 17); and 6) Forward primer F3-3: 5'-CACAGGACGCCGGTAGAGATA-3' (SEQ ID NO: 14) Reverse primer R3-3: 5'-ATGCACCACCTGCACACAG-3' (SEQ ID NO: 16); iii. probe S4, which is selected from: Probe S4-0: 5'-ACATGCTACAATGGCCGG-3' (SEQ ID NO: 9) and Probe S4-1: 5′-ACATGCTACAATGGCCGGT-3′ (SEQ ID NO: 26); Wherein when the probe S4 is S4-1, the third primer pair is selected from: 1) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 2) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 3) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-1: 5'-GGCATCGCAGCCCTTTG-3' (SEQ ID NO: 8); 4) Forward primer F4-1: 5'-CCCTTATGTCCAGGGCTTCA-3' (SEQ ID NO: 7), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 5) Forward primer F4-3: 5'-CCCCTTATGTCCAGGGCTTC-3' (SEQ ID NO: 18), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); 6) forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-3: 5'-CGGCATCGCAGCCCTT-3' (SEQ ID NO: 20); and 7) Forward primer F4-5: 5'-GCCCCTTATGTCCAGGGC-3' (SEQ ID NO: 19), reverse primer R4-6: 5'-GGCATCGCAGCCCTTTGTA-3' (SEQ ID NO: 21).

15. A method for producing a biopharmaceutical product, the method comprising the step of testing for mycobacterial contamination by performing the method according to any one of claims 9 to 14.